

BEACON

ANNUAL REPORT 2013



www.beacon-pharma.com

ANNUAL REPORT 2013



ANNUAL

REPORT 2013



Our Mission

To improve the quality of human life by providing innovative pharmaceutical products through continuous research and development ensuring stakeholders satisfaction.

Our Vision

To be regarded and recognized as one of the most value - driven Pharmaceuticals Companies in the world.

Our Values

Quality in everything we do

Live up to our commitment

Trust & respect for each other

Transparent & fair in all our dealings

Take initiative to exceed standard

Work as a team

Share social responsibilities

Our Goals

To be the market leader.

Serve our customers with quality products at a reasonable price.

Develop our employees with high potentials and an opportunity of career development.

Establish strong regional presence.

Provide our shareholders a steady asset growth and return on investment.

Recognize the suppliers as our business partners and Competitors as the contributor to the market value.

Grow revenue and profit.





Corporate Office:

153-154 Tejgaon I/A, Dhaka-1208, Bangladesh

Tel : +880-2-8870133, +882-2-8870134

Fax : +880-2-8870109

E-mail : beacon@beacon-pharma.com

Website : www.beacon-pharma.com

Letter of Transmittal

To
The Shareholders
Securities and Exchange Commission
Registrar of Joint Stock Companies & Firms
Dhaka Stock Exchange Ltd.
Chittagong Stock Exchange Ltd.

Subject: Annual Report for the year ended 30th June, 2013.

Dear Sir,

We are pleased to forward a copy of Annual Report together with Financial Statements for the year ended 30th June, 2013 for your kind information and record.

Sincerely yours,



Giash Uddin Ahmed, FCMA
Company Secretary

Content

01

Corporate Management 08-16

Corporate Directory

Board of Directors

Management Team

4 Years Financial Highlights

Notice of the 12th Annual General Meeting

02

Corporate Governance 17-41

Message from the Chairman

Statement of Managing Director

Directors' Report to the Shareholders

Audit Committee Report

Corporate Governance

The principles of transparency and accountability

Annexure I-III

Directors' Responsibilities for the
Financial Statements

42-51

Our Team

Production line
Production Team
New Arrivals
Our Products
Marketing Team &
General workforce

03

52-78

Financial Statements

Auditors' Report
Statement of Financial Position
Statement of Comprehensive Income
Statement of Changes in Equity
Statement of Cash Flow
Notes to the Financial Statements

04

79-84

Additional Information

Proxy Form
Attendance Slip

05



CORPORATE MANAGEMENT

Corporate Directory

Board of Directors

Mrs. Nurun Nahar Karim, Chairman
Mr. Md. Ebadul Karim, Managing Director
Mr. Md. Niazul Karim, Director
Mr. Abdul Qader Siddiqui, Independent Director

Board Audit Committee

Mr. Abdul Qader Siddiqui, Chairman
Mr. Md. Ebadul Karim, Member
Mrs. Nurun Nahar Karim, Member
Mr. Giash Uddin Ahmed FCMA, Secretary

Management Team

Miss. Risana Karim, Director
Mr. Giash Uddin Ahmed FCMA, SVP, Finance & Accounts
Mr. A.K.M. Anwarul Haq, SVP, Marketing
Mr. Shahidul Islam, SVP, Factory Operation
Mr. Monjurul Alam, VP, International Business Development
Mr. Mohammad Ashraful Islam, VP, Quality Assurance
Mr. Mohammad Anisur Rahman Khan, Senior Manager, HR & Admin
Mr. Md. Safiul Islam, Senior Manager, MIS & Market Audit
Mr. Sujit Kumar Kundo, Senior Manager, Product Development
Mr. Saiful Islam, Senior Manager, Production

Company Secretary

Mr. Giash Uddin Ahmed, FCMA

Auditors

M/S. Habib Sarwar & Company, Chartered Accountants
Eastern Commercial Complex, 73 Kakrail, 7th Floor, Dhaka -1000.

Legal advisor

Abul Khayer & Associates, 25/A Indira Road, Farmgate, Dhaka.

Listing

Dhaka Stock Exchange Ltd., Chittagong Stock Exchange Ltd.

Registered Office

153 -154 Tejgaon I/A., Dhaka-1208, Bangladesh.
Tel: +880-2-8870133, 8870134, Fax: +880-2-8870109
E-mail: beacon@beacon-pharma.com, Website: www.beacon-pharma.com

Factory

Kathali, Bhaluka, Mymensingh


Main Banker

Janata Bank Limited, Corporate Bhaban Branch, Dhaka



Mrs. Nurun Nahar Karim
Chairman

Mrs. Nurun Nahar Karim is an MA. She is the wife of Mr. Md. Ebadul Karim. Mrs. Nurun Nahar Karim is associated with a number of business and Industrial ventures which includes among others Beacon Pharmaceuticals Limited, Beacon Development Ltd. and Kohinoor Chemicals Co. (BD) Ltd. She is the Director of the above three Companies.



Mr. Md. Ebadul Karim
Managing Director

Mr. Md. Ebadul Karim, a Arts Graduate entered into the realm of business horizon after completion of his graduation. By virtue of his entrepreneurial skill and sound management capability accompanied with vast experience and farsighted vision he has been running a number of enterprises very successfully. He is Managing Director of Beacon Pharmaceuticals Limited and also the Managing Director of Beacon Development Ltd., a reputed Real Estate Development Company. He is also the Director of Kohinoor Chemicals Co. (BD) Ltd., one of the largest and leading soaps, cosmetics and toiletries manufacturing company in the Country. He has travelled many countries of the world for business purposes.



Mr. Md. Niazul Karim
Director

Mr. Md. Niazul Karim, S/O. Mr. Md. Ebadul Karim is a BBA completed from the American International University of Bangladesh. Just after completing his BBA he has actively involved in the business and presently he is acting as the Director of Beacon Pharmaceuticals Ltd. and Beacon Development Ltd.



Mr. A. Q. Siddiqui
Independent Director

Mr. A.Q. Siddiqui is an M.A in Economics from the University of Dhaka. He did his Diploma from the Institute of Bankers in Pakistan. He is a fellow of UNADI and IBB and also a Council member of IBB. Mr. Siddiqui is the Chairman of Bangladesh Commerce Bank Ltd., He is also the Country Chief Representative of Habib Bank AG Zurich an International Bank incorporated in Switzerland. He was the Managing Director of Sonali Bank Ltd., Agrani Bank Ltd. and also the Dy. Managing Director of Janata Bank Ltd.

Board of Directors

Management Team



Miss. Risana Karim
Director



Mr. Giash Uddin Ahmed
Senior Vice President
Finance & Accounts and
Company Secretary

Management Team



Mr. A.K.M. Anwarul Hoq
Senior Vice President
Marketing



Mr. Md. Shahidul Islam
Senior Vice President
Factory Operation



Mr. Monjurul Alam
Vice President
International Business Development



Mr. Mohammad Ashraful Islam
Vice President
Quality Assurance

Management Team



Mr. Mohammad Anisur Rahman Khan
Senior Manager
HR & Admin



Mr. Md. Safiul Islam
Senior Manager
MIS & Market Audit



Mr. Sujit Kumar Kundo
Senior Manager
Product Development



Mr. Saiful Islam
Senior Manager
Production

4 (four) Years Financial Highlights

Particulars	Year			
Financial Performance	2013	2012	2011	2010
Total Assets	4,251,619,886.00	4,511,424,780.00	4,332,423,471.00	3,652,158,283.00
Total Liabilities	1,478,361,558.00	1,747,297,518.00	1,643,557,370.00	1,365,305,530.00
Current Assets	1,526,460,823.00	1,558,681,879.00	1,404,708,549.00	1,120,732,011.00
Current Liabilities	702,348,389.00	897,220,836.00	739,138,766.00	426,521,195.00
Non-Current Assets	2,565,178,873.00	2,952,742,901.00	2,929,714,922.00	2,531,426,272.00
Non-Current Liabilities	776,013,169.00	850,076,683.00	904,418,604.00	938,784,335.00
Shareholders' Equity	2,773,258,328.00	2,764,127,262.00	2,688,866,101.00	2,286,852,753.00
Operational Performance				
Revenue	1,226,906,195.00	979,436,050.00	734,972,610.00	554,265,199.00
Cost of Goods Sold	609,987,995.00	452,583,791.00	334,079,394.00	255,198,994.00
Operating Expense	409,526,225.00	187,064,433.00	134,377,825.00	109,825,711.00
Financial Expense	196,958,236.00	212,120,046.00	174,047,807.00	169,096,748.00
Gross Profit	616,918,200.00	526,852,259.00	400,893,216.00	299,066,205.00
Operating Profit	207,391,975.00	339,787,826.00	266,515,391.00	189,240,494.00
Net Profit before tax	14,609,706.00	120,417,857.00	137,968,721.00	24,114,850.00
Net Profit after tax	9,131,066.00	75,261,161.00	111,601,475.00	24,114,850.00
Financial Ratio				
Current ratio	2.17:1	1.73:1	1.90:1	2.62:1
Debt Equity Ratio	1:1.88	1:1.58	1:1.63	1:1.67
Financial Expense Coverage Ratio (Times)	1.05	1.60	1.53	1.12
Return on Equity	0.33%	2.72%	4.15%	1.05%
Return on Assets	0.21%	1.67%	2.58%	0.66%
Equity Parameters				
Authorized Capital	3,000,000,000.00	3,000,000,000.00	2,500,000,000.00	2,500,000,000.00
Paid-up Capital	2,310,000,000.00	2,310,000,000.00	2,200,000,000.00	1,900,000,000.00
Shareholders' Equity	2,773,258,328.00	2,764,127,262.00	2,688,866,101.00	2,286,852,753.00
No. of Shares Outstanding	231,000,000.00	231,000,000.00	220,000,000.00	190,000,000.00
Net Assets Value (NAV) Per Share	12.01	11.97	12.22	12.04
Earnings Per Share (EPS)	0.04	0.33	0.51	0.13
Market Price Per Share (Closing)	14.10	19.10	32.10	N/A
Price Earnings Ratio (Times)	352.50	57.88	62.94	N/A



NOTICE OF THE 12th ANNUAL GENERAL MEETING

Notice is hereby given that the 12th Annual General Meeting of the shareholders of Beacon Pharmaceuticals Limited will be held on Wednesday, 18th December, 2013 at 10.00 a.m at its Factory Premises at Kathali, Bhaluka, Mymensingh to transact the following business:

Agenda:

1. To receive, consider and adopt the Directors' and Auditors' Report and the Audited Accounts of the Company for the year ended 30th June, 2013.
2. To declare dividend for the year ended 30th June, 2013.
3. To elect Directors.
4. To appoint Auditors and fix their remuneration.
5. To approve the appointment of Independent Director.
6. To transact any other business with the permission of the Chair.

By the order of the Board

Giash Uddin Ahmed, FCMA
Company Secretary
4th November, 2013

Registered Office
153-154 Tejgaon I/A.,
Dhaka-1208, Bangladesh

Notes:

1. Shareholders whose names appeared at the record date i.e 13th November, 2013 in the share register of the Company or in the depository register on that date will be eligible to attend and vote in the Annual General Meeting.
2. Member entitled to attend vote at the Annual General Meeting may appoint a proxy to attend and vote on his/her behalf. The proxy form must be affixed with requisite revenue stamp and must be submitted to the registered office of the Company not later than 48 hours before the time fixed for the Annual General Meeting.
3. Admission in the meeting venue will be allowed on production of the attendance slip attached with the proxy form.



Corporate Governance



Message from the Chairman





Message from the Chairman

It is my great pleasure to place before you the Annual Report along with the Audited Financial Statements of the Company for the year ended 30th June, 2013. Hefty devaluation of taka against us dollar, crushing of capital market, liquidity crisis in the commercial banks, high bank interest rate and unrest in the national and international politics has made an obstacle in the development of Bangladesh economy. The politics of confrontation rather than politics of conciliation and mutual accommodation have created havoc for common people. We will not be able to grasp the advantage that lay before us if this confrontation continues. Economic activities are being hampered, generating a lot of anxieties and sense of insecurities amongst the businessmen and general public. This has affected economic growth, reduced investment and increased unemployment.

In spite of having these dangers our loyal and dedicated workers and employees overcome most of the adverse situations taken place through their relentless effort and out of a sense of belongingness with the Company presented a very small result with a commitment for the better in the future. On behalf of the Board and on my own behalf I congratulate and thanks to the valued shareholders, outside stakeholders, customers and employees at all levels.

Nurun Nahar Karim

Nurun Nahar Karim
Chairman

Statement of Managing Director





Statement of Managing Director

Dear Shareholders,

Bangladesh Economy has been passing through a very hard time due to hefty devaluation of taka against us dollar, crushing of capital market, liquidity crisis in the commercial banks, high bank interest rate and unrest in the national and international politics. The overall adverse economic condition effects the import ingredients to become costlier and the ultimate result of operational activities is the downsizing of margin. In order to face these economic challenges we have given special emphasis on cost control, resource optimization and R & D capabilities. Despite of facing a number of challenges, we have achieved the targeted sales growth.

Operating Result:

1. Sales Turnover has been increased by 25% over last year.
2. Gross Profit has been increased by 17% over last year.
3. Operating Profit has been reduced by 38.96% over last year.
4. Net Profit after tax has been decreased by 87.86% over last year.
5. Net Asset value per share has been reduced by 87.87% over last year.

New Products:

In 2006, Beacon pharmaceuticals Ltd. started its Journey with the vision to manufacture anticancer & imported life saving medicines in Bangladesh.

Besides launching of new generation medicinal products for the first time in Bangladesh, Beacon Pharma always strives for the introduction of the newer & latest technologies in Bangladesh. Consistent to our committed efforts to cater to the healthcare needs for our people in 2013, we had successfully launched 17 new products which are going to contribute in revenue earning in 2014. There are 9 general products & 8 oncology products introduced in Bangladesh Pharma market of which 7 are new molecules (introduced for the first time in Bangladesh). In 2013, we have proudly introduced one of the most sophisticated & modern drug delivery systems till date for the first time in Bangladesh "The Liposomal Drug Delivery System". And the product name is Tericin, the preparation of Amphotericin-B used for systemic fungal infection. We think Tericin is a land mark product not only for Beacom Pharma but also for the Pharmaceutical Industry in Bangladesh.

As a sophisticated pharmaceutical company, we focus our efforts where we can have the most impact. Our products are of different therapeutic segments like Milran (Milnacipran) for fibromyalgia, Medrina (Medroxy progesterone) for menstrual problems of female, Xentoin (Phenytoin) for epilepsy & seizure, Infusion and Infusion Plus (Dextrose infusion) for fluid & electrolyte replenishment, Migratol (Tolfenamic acid) for migraine pain & headache, Tericin (Amphotericin-B) for systemic fungal infection, Zytix (Abiraterone) for prostate



Statement of Managing Director

cancer, Rituxim (Rituximab) for blood cancer, Temonix (Temozolomide) for brain tumor, Bivastim (Bivasizumab) for lung cancer, Trastunix (Trastuzumab) for Breast cancer, Cytabin (Cytarabin) for leukemia, Ifosfamide (Zifos) for testicular cancer etc.

We are confident that your Company will continue to outperform industry growth in the coming years with continuous and successful expansion of product portfolio.

Beacon's export business is growing fast

Beacon Pharmaceuticals Limited has initiated its operation with the tagline, "A company with global vision". It didn't take long for Beacon to pave its path into that direction. We have started our international operations in 2010 and within this short period of time, Beacon has been able to establish its operation in 10 countries.

In 2013, Beacon has earned more than six hundred thousand dollar (US) through export of its products in 10 different countries. Despite of global economic recession throughout the world, our International sales has grown by 245% over last year. The most positive virtue is that majority of our International sales came from Oncology portfolio. This shows that our oncology products are compliant with international quality standards.

Among the 10 countries, our operations went very well in Philippines. We have been able to establish our Gemoxen (gemcitabine) brand as one of the leading gemcitabine brand in Philippines. Next to Philippines, we performed well in Sri Lanka. In 2013, we have started our operations in Vietnam, Nepal & Ghana. It is indeed a matter of pride that our Xbac (ciprofloxacin) PFS is included in the National Health Formulary of Ghana Ministry of Health. This is the only Bangladeshi product included in the National Formulary of Ghana.

Besides these mentioned countries, we are also performing well in Myanmar & Uzbekistan. Registrations of our products are also going on in Hong Kong, Cambodia, Puerto Rico, Mauritania, Bhutan and Mongolia and registration of second phase products are commencing in the existing countries.

We are keen to enter into regulated countries like Singapore, Malaysia, and Australia. In view of this, we have started the proceedings for PICs certification. Globally renowned regulatory firm, Seer Pharma (Australia) is conducting the training session of our plant staff. In addition, we have a plan to go for UK MHRA certification after completion of PICs.

A number of local and International organizations have shown interest for contract manufacturing of Hi-Tech products at our plants. We have started for 2 local companies and hoping to start for a number of international companies from different countries in 2014.

We are pleased to inform that very soon we will be able to open up a new area of business through Technology Transfer. Negotiations with a number of countries are commencing for transfer of technology of our Hi-Tech life saving drugs. It will be the first time for any Bangladeshi Pharmaceutical company to initiate a project like this.



Statement of Managing Director

We have engaged foreign sales team in Sri Lanka and Nepal to promote our brands. This year we have started a program under which our field force from these countries were trained by our professional Marketing and IBD team.

In 2013, a number of foreign collaborators have visited our facilities which include Saudi Prince, Belarus Health Minister and Ambassador from Nigerian Embassy in India along with their teams. All of them were much impressed to see our facilities and have shown interest to establish joint venture facilities with Beacon in their respective countries.

Like local market, Beacon has also started to do well in International business. I am sure that if we continue our good works, in very near future we will be able to make Beacon a Global Company.

Project Expansion:

We have submitted a BMRE Proposal to the Bank for a new Syrup Line of the children and enhancement of Oncology Capacity including the Hormone Project which is under active consideration of the consortium partner of the lead Bank. On having the approval of the same, the project implementation work will run in a full swing.

Conclusion:

Whatever we have achieved so far is the reflection of outstanding contribution of the employees of Beacon Pharma. I would like to thank all of them for their utmost co-operation, dedication and commitment. Before I conclude I like to take the opportunity to express my sincere thanks with gratitude to all of our valued customers, bankers, financial institutions, suppliers, healthcare professionals, government agencies, regulatory bodies and everyone who has interaction with Beacon Pharma and its continuous progress.

Finally, I like to thank to our valued shareholders who continue demonstrate their belief in the potential of the Company.

I also look forward to having continuous support from you all.

Thank you all,



Md. Ebadul Karim
Managing Director



Directors' Report to the Shareholders

For the year ended 30th June, 2013

Dear Shareholders

The Directors have the pleasure in presenting their Annual Report together with the Audited Financial Statements of the Company for the year ended 30th June, 2013. These were approved by the Board of Directors on 24th October, 2013. The Directors' Report has been prepared in compliance with section 184 of the Companies Act, 1994, SEC's notification dated 7th August 2012, the Listing Regulations of Dhaka and Chittagong Stock Exchange and other applicable rules and regulations. In addition, the Directors explained and disclosed certain issues, which they deemed relevant and important to ensure transparency and good governance practice.

Industry outlook and possible future development in the industry

The principal activities of the Company are to manufacturing and marketing of pharmaceuticals and lifesaving medicine in the local and international markets. Beacon is the first manufacturer of anti-cancer drugs in Bangladesh and proud introducer of isolator technology for processing anti-cancer products and Lyophilized Technology. Beacon is the second in world to manufacturing and marketing peginterferon medicine for hepatitis. Beacon is the first to introduce sophisticated biotech products streptokinase and Urokinase injections for Acute MI disease. This year Beacon has launched 17 nos. of new products, out of which 9 general products, 8 oncology products.

Hefty devaluation of taka against us dollar, crushing of capital market, liquidity crisis in the commercial banks, high bank interest rate and unrest in the national and international politics has made an obstacle in the development of Bangladesh economy. The politics of confrontation rather than politics of conciliation and mutual accommodation have created havoc for common people. We will not be able to grasp the advantage that lay before us if this confrontation continues. Economic activities are being hampered, generating a lot of anxiety and sense of insecurity amongst the businessmen and general public. This has affected economic growth, reduced investment and increased unemployment.

In spite of having these dangers our loyal and dedicated workers and employees overcome all the adverse situation taken place through their relentless effort and out of a sense of belongingness with the Company presented a very small result with a commitment for the better in the future.

Margin Analysis

Cost of goods sold for the year stands at Tk. 60,99,87,995.00 which is 35% higher than that of the previous year. This has been occurred due to increase of sales by 25% compare to the previous year and substantial increase in cost of material, labor and factory overhead, as a result Gross Margin has been increased only by 17% over the previous year, which should have been more. Due to huge increase in operating expense net margin has been reduced substantially.

Extra-Ordinary Gain or Loss

No extra ordinary gain or loss occurred during the year which would require adjustment or disclosure in the financial statements.



Directors' Report to the Shareholders

For the year ended 30th June, 2013

Related Party Transaction

Related Party Transactions are disclosed in the notes 33.12 to the Financial Statements for the year ended 30th June, 2013.

Utilization of Proceeds from Public Issue / Right Issue and /or through any instruments

During the period no such proceeds are collected that would require for adjustment or disclose in the annual report.

Financial Results Deteriorate after the Company goes for Initial Public Offering, Repeat Public Offering, Right Issue and Direct Listing.

Beacon Pharmaceuticals Limited went for initial public offering in the year 2010 and did not go for any sorts of offering since then. So, no such explanation is required for the company.

Significance variance occurs between Quarterly Financial Performance and Annual Financial Statements

There was no significant variance occurred between the quarterly financial performance and annual financial statements of the company

Fairness of Financial Statements

The financial statements together with the notes thereon have been drawn up inconformity with the Company's Act 1994 and the Securities and Exchange Rules 1987. These statements present fairly the Company's state of affairs, the result of operation, cash flow and changes in equity.

Books of accounts

Books of Accounts of the Company have been maintained properly.

Accounting Policies

Appropriate accounting policies have been consistently applied in preparation of the financial statements and the accounting estimates are based on reasonable and prudent judgment.

Application of IAS/BAS/IFRS/BFRS

International Accounting Standard (IAS)/ Bangladesh Accounting Standard (BAS)/ International Financial Reporting Standard (IFRS)/ Bangladesh Financial reporting Standards (BFRS) as applicable in Bangladesh have been followed in preparation of the financial statements and any departure therefrom has been adequately disclosed.

The System of Internal Control

The systems of internal controls are sound and have been implemented and monitored effectively. The Board has the ultimate responsibility for Beacon Pharma's system of internal control and for reviewing its effectiveness. It has been designed to manage the risk of failure to achieve the objectives of the Company and to provide reasonable assurance that Company's assets are safe guarded against unauthorized use of material loss and

Directors' Report to the Shareholders

For the year ended 30th June, 2013

that transactions are properly authorized and recorded.

Going Concern

There is no significant doubt about the Company's ability to continue as a going concern. The Board of Directors has reviewed the Company's business plan and is satisfied that the Company has adequate resources to continue its operations in the foreseeable future. Accordingly the financial statements are prepared based on the Going Concern concept.

Deviation from the last year's operating result

Significant variations over the last year's operation of the Company have been made due to excess expenditure incurred in the factory overhead, general & admin overhead and selling and distribution overhead. The positive impact of excess expenditures are yet to come. Hopefully the growth of turnover will dramatically change in the years to come.

Key operating and financial data preceding 4 (four) years

The key operating and financial data for the last 4 (four) years have been presented on the page no 15

Dividend

The Board of Directors of the Company has not recommended any dividend for the year ended

30th June, 2013 since the Company does not make such profit to pay dividend for the year.

Number of Board Meeting held

During the year 13 nos. of Board Meeting were held. The attendance record of the Directors is shown in the annexure - III of this report. The Directors who could not attend the meeting were granted leave of absence.

Pattern of Shareholding

The pattern of shareholding is shown in the annexure -II of this report.

Recommendation for re-appointment of Directors

As per provision of the Articles of Association of the Company Mr. Md. Niazul Karim will retire by rotation in the next 12th Annual General Meeting and being eligible offered himself for re-appointment. As per Regulation no. 54 of schedule 1 of the Company's Act 1994 and condition no. 1.4 of the BSEC Notification No. SEC/CMRRCD/2006-158/134/Admin/44, dated 7th August, 2012 Mrs. Nurun Nahar Karim, Director of the Company has been appointed as Chairman of the Company for the next 5 (five) years as recommended by the Board of Directors of the Company.

Appointment of Auditors

Pursuant to section 210 of the Companies Act 1994, The Company's statutory Auditors Messrs. Sarwar Habib & Co., Chartered Accountants will retire at the 12th Annual General Meeting as auditor of the Company.

The retiring Auditors are eligible for re-appointment and have express their willingness to continue in the office. The Directors recommended for the appointment of Messrs. Sarwar Habib & Co., Chartered Accountants as the Auditors



Directors' Report to the Shareholders

For the year ended 30th June, 2013

of the Company for the year 2014.

Corporate Governance Compliance Report

In accordance with the requirement of the Securities and Exchange Commission, "Corporate Governance Compliance Report" is shown in the annexure - I of this report.

Conclusion

The Company expresses its sincere appreciation to all of its employees for their outstanding contribution and at the same time thank to all the stakeholders for their continued support and confidence.

Approved by the Board of Directors and signed on its behalf.



Md. Ebadul Karim
Managing Director

Audit Committee Report

Composition of Audit Committee

The Board of Directors of Beacon Pharmaceuticals Limited has formed an Audit Committee comprising the following three Directors as per Notification No. SEC/CMRRCD/2006-158/134/Admin/44, dated 7th August, 2012 of Bangladesh Securities and Exchange Commission :

Mr. A. Q. Siddiqui (Independent Director) - Chairman of the Committee, Mrs. Nurun Nahar Karim - Member., Mr. Md. Ebadul Karim - Member and Mr. Giash Uddin Ahmed FCMA - Secretary of the Audit Committee.

Role and Responsibility of the Audit Committee

The Audit Committee is empowered to consider any matter relating to the financial affairs of the Company and to review all internal and external audit, internal control system, procedures and accounting policies etc of the Company so as to ensure that a sound financial reporting system is in place in order to provide an accurate, appropriate and timely information to the Management, Regulatory Authorities and to the Shareholders.

Meetings held of the Audit Committee

A number of meetings were held of the Audit Committee during the year where a detailed discussion was made relating to quarterly and final accounts of the Company.

Activities of Audit Committee

The following activities were carried out by the Audit Committee during the financial year as per terms of reference of the audit committee.

Financial Reporting:

Reviewed the quarterly, half yearly and third quarter accounts of the Company.

Reviewed the final accounts of the Company prior to submission to the Board of Directors for approval. The review was to ensure that financial reporting and disclosures were in compliance with the Securities Laws, provision of Company's Act 1994, applicable Accounting Standards / IFRS, any conflict of interest and other relevant legal and regulatory requirements.

Internal Audit:

Reviewed the annual audit plans including the audit methodology, scope and coverage of audit activities of the Company.

Reviewed the effectiveness of audit process, resource requirements and assess the performance of internal audit department. The competency and performance of the Head of Internal Audit is also reviewed.

Reviewed the internal audit report which encompassed the audit issues, audit recommendations and management's response to these recommendation, actions taken in the area of internal control system and efficiency enhancement suggested by the internal auditors.

External Audit:

The Committee met with the external auditors at the conclusion of the Final Accounts and reviewed their findings and management response. The Committee also reviewed the external auditors report and areas of concern they

Audit Committee Report

highlighted in the management letter and management's response to the findings of the external auditors.

Internal Control System

The Committee also reviewed the effectiveness of internal control system of the Company and put their valuable suggestions to develop the system in order to safeguard the Company's assets and outstanding financial performance.

Recommendation

The Audit Committee recommended to the Board of Directors that M/S. Habib Sarwar & Co., Chartered Accountants may be appointed as auditors of the Company for the financial year 2013-14 subject to the approval of the members of the Company at the 12th Annual General Meeting.

On behalf of the Audit Committee



A. Q. Siddiqui
Chairman of the Audit Committee

Corporate Governance

The Guidelines of Transparency and Accountability

Corporate Governance

Adopting the best practice of Corporate Governance and follows the principles of transparency and accountability that protect the interest of its stakeholders and safeguarding the assets of the shareholders. Corporate Governance ensures the activities that led the Company to its goal through setting strategies, formulating policies and taking prudent decisions. The Board of Director of Beacon ensure that the activities undertaken by the Company are in accordance with the highest ethical standards in the best interest of all stakeholders.

The Board

The Board comprises of four members of executive and non-executive having diverse and professional skill and experience. The non-executive Directors are from different business and background. Their experience enable them to contribute the Company in making strategy, formulating policy and other decision making process for advancement. The Chairman is the head of the Board and Company Secretary is the compliance officer who prepare agenda in consultation with the Chairman of the Board Director and Chairman of various Committee and Managing Director. The Chairman ensures that all Board members are properly briefed on all issues raise in the Board Meeting. It is the responsibility of the Chairman and the Company Secretary to ensure that the non-executive Directors are provided with timely information to enable them to carry the duties effectively.

Board Meetings

The Board of Directors has the supreme authority delegated by the shareholders in making strategy, formulating policy and other decision making process for development of the Company. The Board of Directors consider that it meets regularly to discharge their duties effectively.

Board Independence

As per Corporate Governance Guidelines, Mr. Abdul Qader Siddiqui has been re-appointed as an Independent Director of the Company. He is considered by the Board to be independent of the Company and the management and free of any business or other relationship that could interfere with the exercise of his independent judgment. The Board beliefs that his experience and knowledge enables him to provide effective and constructive contribution to the Board.

Board Committee

The Board of Directors has formed committees to assist in exercising its authority including monitoring of performance.

Board Audit Committee

The Company's audit committee met fourth times in 2013 to consider its Annual Financial Statements for the year ended 30th June, 2013 and the Quarterly Reports in the same financial year. The committee comprises Mr. Abdul Qader Siddiqui, Mr. Md. Ebadul Karim and Mrs. Nurun Nahar Karim.

Internal Control

The Board has the ultimate responsibility for Beacon Pharma's system of internal control and for reviewing its effectiveness. It has been designed to manage the risk of failure to achieve the objectives of the Company and to provide reasonable assurance that Company's assets are safe guarded against unauthorized use of material loss and that transactions are properly authorized and recorded.

Annexure - I

Status of compliance with the conditions imposed by the Commission's Notification No. SEC/CMRRCD/2006-158/134/Admin/44 dated 7th August, 2012 issued under section 2CC of Securities and Exchange Ordinance 1969 (Report under Condition No. 7.00)

Condition No.	Title	Compliance Status	Remarks (if any)
1.	BOARD OF DIRECTORS		
1.1	Board's Size The number of the board members of the company shall not be less than 5 (five) and more than 20 (twenty);	Not Complied	Under process
1.2	Independent Directors:		
1.2 (i)	At least one fifth of Directors should be Independent Directors;	Complied	
1.2 (ii)	a Independent Director does not hold any share or holds less than 1% share of the total paid-up capital;	Complied	
1.2 (ii)	b Non connectivity with the company's sponsor or director or shareholder Who holds 1% or more shares on the basis of family relationship.;	Complied	
1.2 (ii) c	Does not have any other relationship, whether pecuniary or otherwise, with the company or its subsidiary/associated companies;	Complied	
1.2 (ii) d	Not a member, director or officer of any member of stock exchange;	Complied	
1.2 (ii) e	Not a shareholder, director or officer of any member of stock exchange or any intermediary of the capital market;	Complied	
1.2 (ii) f	Not a partner or an executive during preceding 3 years of the company's statutory audit firm.;	Complied	
1.2 (ii) g	Shall not be an Independent Director in more than 3 listed companies;	Complied	

Annexure - I

Condition No.	Title	Compliance Status	Remarks (if any)
1.2 (ii) h	Non convicted by court of competent jurisdiction for defaulting any loan payment to a bank/ non- banking financial institution.;	Complied	
1.2 (ii) i	Non convicted for a criminal offence involving moral turpitude;	Complied	
1.2 (iii)	Appointment of Independent Director shall be by board of directors and subsequently approved by shareholders in the AGM;	Complied	
1.2 (iv)	The post of Independent Director(s) cannot remain vacant for more than 90 (ninety) days.	Complied	
1.2 (v)	Code of conduct for all Board members and compliance matter;	Complied	
1.2 (vi)	Tenure of office of an Independent Director (for a period of 3 years, may be extended for 1 term only);	Complied	
1.3	Qualification of Independent Director:		
1.3 (i)	Shall be a knowledgeable individual with integrity who is able to ensure Compliance with financial, regulatory and corporate laws and can make meaningful contribution to business;	Complied	
1.3 (ii)	Should be a Business/Corporate Leader/Bureaucrat/University Teacher With Economics or Business Studies or Law background/ Professionals like Chartered Accountants, Cost & Management Accountants, Chartered Secretaries. Must have at least 12 (twelve) years of corporate management/ professional experiences;	Complied	
1.3 (iii)	Relaxation of qualifications of Independent Directors subject to prior approval of the Commission.		Not Applicable
1.4	Chairman of the Board and Chief Executive Officer shall be different Individual with clearly defined respective roles and responsibilities.	Complied	

Annexure - I

Condition No.	Title	Compliance Status	Remarks (if any)
1.5	The Directors' Report to Shareholders:		
1.5 (i)	Industry outlook and possible future developments in the industry;	Complied	
1.5 (ii)	Segment-wise or product-wise performance;	Complied	
1.5 (iii)	Risks and concerns;	Complied	
1.5 (vi)	A discussion on Cost of Goods sold, Gross Profit Margin and Net Profit Margin;	Complied	
1.5 (v)	Discussion on continuity of any Extra-Ordinary gain or loss;		Not Applicable
1.5 (vi)	Disclosure on related party transactions;	Complied	
1.5 (vii)	Utilization from public issues, rights issues and/or through any others instruments;		Not Applicable
1.5 (viii)	Explanation if the financial results deteriorate after going for IPO, RPO, Rights Offer, Direct Listing, etc.;		Not Applicable
1.5 (ix)	Significant variance between Quarterly Financial performance and Annual Financial Statements and explanation thereon;		Not Applicable
1.5 (x)	Remuneration to directors including independent directors;		
1.5 (xi)	Fairness of financial statements;	Complied	
1.5 (xii)	Maintenance of proper books of account;	Complied	
1.5 (xiii)	Application of appropriate accounting policies and estimates;	Complied	
1.5 (xiv)	Application of International Accounting Standards (IAS)/Bangladesh Accounting Standards (BAS)/International Financial Reporting Standards (IFRS)/Bangladesh Financial Reporting Standards (BFRS);	Complied	
1.5 (xv)	Efficiency of Internal control system;	Complied	
1.5 (xvi)	Going concern (ability to continue as going concern);	Complied	
1.5 (xvii)	Deviations in Operating Results ((highlighting significant deviations from Last year in operating result);	Complied	

Annexure - I

Condition No.	Title	Compliance Status	Remarks (if any)
1.5 (xviii)	Key operating and financial data (summarized financial data of at least preceding three years);	Complied	
1.5 (xix)	Reason for non -declaration of dividend;	Complied	
1.5 (xx)	Number of Board Meetings (nos.of Board Meetings held and attendance by Each director);	Complied	
1.5 (xxi)	The pattern of shareholding;	Complied	
1.5 (xxi)a	Parent/Subsidiary/Associated Companies and other related parties (name wise details);	Complied	
1.5 (xxi) b	Directors, Chief Executive Officer, Company Secretary Chief Financial Officer, Head of Internal Audit and their spouses and minor children (name wise details);	Complied	
1.5 (xxi) c	Executives;	Complied	
1.5 (xxi) d	Shareholders holding ten percent (10%) or more voting interest in the company (name wise details).	Complied	
1.5 (xxii)	Brief resume of Director in case of the appointment/re-appointment:		
1.5 (xxii) a	Brief resume of the director;	Complied	
1.5 (xxii) b	Nature of his/her expertise in specific functional areas;	Complied	
1.5 (xxii) c	Names of companies in which the person also holds the directorship and the membership of committees of the board.	Complied	
2 CHIEF FINANCIAL OFFICER (CFO), HEAD OF INTERNAL AUDIT (HIA) AND COMPANY SECRETARY (CS)			
2.1	Appointment of CFO, HIA & CS and define respective roles, responsibilities And duties of CFO, HIA & CS;	Complied	
2.2	Requirement to attend in the Board meeting of the CFO and CS;	Complied	

Annexure - I

Condition No.	Title	Compliance Status	Remarks (if any)
3	AUDIT COMMITTEE		
3. (i)	Should have an audit committee as a sub-committee of the Board of Directors;	Complied	
3. (ii)	Assisting Board of Directors in ensuring true and fair presentation of Financial statements and also to monitor system;	Complied	
3. (iii)	Reporting and duties of the Audit Committee;	Complied	
3.1	Constitution of the Audit Committee;		
3.1 (i)	Composition of Audit Committee (should be composed of at least 3 (three) members;	Complied	
3.1 (ii)	Audit Committee Members Appointment (members should be appointed by the Board with at least one independent Director);	Complied	
3.1 (iii)	Financially literacy of committee members (members should be financially literate);	Complied	
3.1 (iv)	Terms of Service of Audit Committee (Board to ensure continuity of minimum prescribed number of members);	Complied	
3.1 (v)	Secretary of the committee.	Complied	
3.1 (vi)	Quorum of the Audit Committee meeting (at least 1 Independent Director must present).	Complied	
3.2	Chairman of the Audit Committee:		
3.2 (i)	Chairman of Audit Committee (Board to select Chairman from audit Committee who shall be an Independent Director);	Complied	
3.2 (ii)	Presence of Chairman of the audit committee in the Annual General Meeting.	Complied	
3.3	Role of the Audit Committee:		
3.3 (i)	Oversee the financial reporting process;	Complied	
3.3 (ii)	Monitor choice of accounting policies and principles;	Complied	

Annexure - I

Condition No.	Title	Compliance Status	Remarks (if any)
3.3 (iii)	Monitor internal control risk management process;	Complied	
3.3 (iv)	Oversee hiring and performance of external auditors;	Complied	
3.3 (v)	Review of annual financial statements before submission to the board;	Complied	
3.3 (vi)	Review of quarterly and half yearly financial statement before submission to the board;	Complied	
3.3 (vii)	Review the adequacy of internal audit function;	Complied	
3.3 (viii)	Review statement of significant related party transactions submitted by the management;	Complied	
3.3 (ix)	Review Management Letters/ Letter of Internal Control weakness issued by statutory auditors;	Complied	
3.3 (x)	Reporting utilization of money raised through Initial Public Offering, Repeat Public Offering/Rights Issue in the quarterly financial statements and also to disclose statement of fund utilization for the purpose other than those stated in the offer documents/prospectus.	Complied	
3.4 Reporting of the Audit Committee:			
3.4.1 (i)	Reporting to the Board of Directors		
3.4.1 (ii) a	Report on Conflict of Interest;		Not Applicable
3.4.1 (ii) b	Report on defect in the Internal Control System to the Board of Directors;	Complied	
3.4.1 (ii) c	Suspected Infringement of Laws to the Board of Directors;		Not Applicable
3.4.1 (ii) d	Any Other Matter (out of the above, a-c)		Not Applicable
3.4.2	Reporting to the Authorities-BSEC (if any material impact on the financial Condition & results of operation, unreasonably ignored by the management) .		Not Applicable

Annexure - I

Condition No.	Title	Compliance Status	Remarks (if any)
3.5	Reporting to the Shareholders (disclosure of activities of the audit committee in the annual report).	Complied	
4	EXTERNAL/STATUTORY AUDITORS:		
4 (i)	Appraisal or Valuation Services (none by the external/statutory auditor);	Complied	
4 (ii)	Financial Information System (none by the external/statutory auditor);	Complied	
4 (iii)	Book Keeping or Other Services (none by the external/statutory auditor);	Complied	
4 (iv)	Broker-dealer Services (none by the external/statutory auditor);	Complied	
4 (v)	Actuarial Services (none by the external/statutory auditor);	Complied	
4 (vi)	Internal Audit Services (none by the external/statutory auditor);	Complied	
4 (vii)	Any other Services (none by the external/statutory auditor);	Complied	
4 (viii)	Not to possess any share of the company (none by the external/statutory auditor).	Complied	
5	SUBSIDIARY COMPANY:		
5 (i)	Composition of the Board of Directors of the subsidiary company;		Not Applicable
5 (ii)	Presence of Independent Director of holding company in the Board of subsidiary company;		Not Applicable
5 (iii)	Review the Board meeting minutes of subsidiary company in the Board Meeting of the holding company;		Not Applicable
5 (iv)	Reflection in the holding company's Board meeting minutes about review of the affairs of subsidiary Company;		Not Applicable

Annexure - I

Condition No.	Title	Compliance Status	Remarks (if any)
5 (v)	Review the financial statements of subsidiary company, in particular the investments made by the subsidiary company.		Not Applicable
6	DUTIES OF CHIEF EXECUTIVE OFFICER (CEO) AND CHIEF FINANCIAL OFFICER Certification of CEO and CFO to the Board:		
6 (i) a	Financial statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;	Complied	
6 (i) b	Financial statements present a true and fair view of the company's affairs and are in compliance with existing accounting standards and applicable laws;	Complied	
6 (ii)	No transactions entered into by the company during the year which are fraudulent, illegal or violation of the company's code of conduct.	Complied	
7	Reporting and Compliance of Corporate Governance:		
7 (i)	Certification on compliance of condition of Corporate Governance Guideline of BSEC and reporting to the shareholders;		Not Complied
7 (ii)	Directors' report should state about the compliance with the conditions of the Corporate Governance Guideline of the Commission.	Complied	

Annexure - II

The pattern of shareholding

(i). Parent/ Subsidiary / Associate Companies

Sl. No.	Name	Designation with BPL	Entities where they have interest	No. of share held
1.	Mr. Md. Ebadul Karim	Managing Director	Beacon Development Ltd.	60,000
			Kohinoor Chemical Co.(BD) Ltd.	5,08,750
2.	Mrs. Nurun Nahar Karim	Director	Beacon Development Ltd.	25,000
			Kohinoor Chemical Co.(BD) Ltd.	3,25,265
3.	Mr. Niazul Karim	Director	Beacon Development Ltd.	40,000

(ii). Director, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and their spouse and minor children

Sl. No.	Name	Designation	No. of shares held
1.	Mr. Md. Ebadul Karim	Managing Director	5,82,28,800
2.	Mrs. Nurun Nahar Karim	Director	47,25,000
3.	Mr. Niazul Karim	Director	63,54,000
4.	Company Secretary		Nil
5.	CFO		Nil
6.	Head of Internal Auditor		Nil
7.	Spouse & Minor Children of the above personnel		Nil

(iii) Executive

Sl. No.	Name	Designation	No. of shares held
1.	Mr. Md. Ebadul Karim	Managing Director	5,82,28,800
2.	Mr. Sujit Kumar Kundu	Manager, PD	20,000

(iv). Shareholders holding ten percent (10%) or more voting interest in the Company

Sl. No.	Name	Designation	Percentage	No. of share held
1.	Mr. Md. Ebadul Karim	Managing Director	25.21	5,82,28,800

Annexure - III

Board Meeting and attendance during the year ended 30th June, 2012

Sl. No.	Name of Directors	Meeting held	No. of meeting attended
1.	Mr. Md. Ebadul Karim	13	13
2.	Mrs. Nurun Nahar Karim	13	13
3.	Mr. Niazul Karim	13	13
4.	Mr. Abdul Qader Siddiqui	13	04

Directors' Responsibilities for the Financial Statements

The Directors are responsible for preparing the annual report and financial statements in accordance with the Company's Act.1994, Securities and Exchange Commission Rules 1987, Bangladesh Financial Reporting Standards (BFRS) and other applicable laws and regulations.

The Company's Act. 1994 requires Directors to ensure that the Company keeps proper books of accounts of all transactions and prepares financial statements that give a true and fair view of the state of the Company's affairs and of the profit for the year.

The Directors are also required to ensure that the financial statements have been prepared and presented in accordance with the International Financial Reporting Standards (IFRS) and the Bangladesh Financial Reporting Standards (BFRS) as applicable in Bangladesh and provided the information required by the Company's Act 1994, Securities and Exchange Ordinance 1969, Securities and Exchange Commission Rules 1987 and the regulations of Dhaka / Chittagong Stock Exchanges. They are also responsible for taking reasonable measures to safeguard the assets of the Company, and in that context to have proper regard to the establishment of the appropriate system of internal control with a view to preventing and detecting fraudulent activities and other irregularities.

The Directors are of the view that these financial statements have been prepared under the generally accepted accounting principles and in accordance with the Bangladesh Accounting Standards as laid down by the Institute of Chartered Accountants of Bangladesh,

Directors endeavor to ensure that the Company maintains sufficient records to be able to disclose, with reasonable accuracy, the financial position of the Company and to be able to ensure that the financial statement of the Company meet with the requirement of the Company's Act 1994, Bangladesh accounting Standards and the regulations of the Dhaka / Chittagong Stock Exchanges.

The Directors have a reasonable expectation, after making enquiries and following a review of the Company's plan for the ensuing year including cash flows and borrowing facilities, that the Company has adequate resources to continue in operational existence for the foreseeable future, and therefore continues to adopt the going concern basis in preparing the accounts.

M/S. Habib Sarwar & Co. Chartered Accountants, Auditors of the Company, have examined the financial statements made available by the Board of the Directors together with relevant financial record, related data, minutes of the Shareholders and Directors meeting and expressed their opinion in their report.

By order of the Board,

Beacon Pharmaceuticals Ltd.,



Md. Ebadul Karim
Managing Director

FINANCIAL STATEMENTS



FINANCIAL STATEMENTS

Independent Auditors' Report To the Shareholders of BEACON Pharmaceuticals Ltd.

We have audited the accompanying financial statements of **BEACON PHARMACEUTICALS LTD.**, consisting of the statement of financial position as at June 30, 2013, and the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Bangladesh Financial Reporting Standards (BFRS), and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Bangladesh Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Opinion

In our opinion, the financial statements present fairly, in all material respects, the financial position of Beacon Pharmaceuticals Ltd. as at June 30, 2013, and its financial performance and its cash flows for the year then ended in accordance with Bangladesh Financial Reporting Standards and comply with the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations.

We also report that:

- a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) In our opinion, proper books of account as required by law have been kept by the company so far as it appeared from our examination of those books;
- c) The company's Statement of Financial Position and Statement Of Comprehensive Income dealt with by the report are in agreement with the books of account and returns; and
- d) The expenditure incurred was for the purposes of the company's business.



Habib Sarwar & Co. Dhaka:
October 24, 2013
Chartered Accountants

FINANCIAL STATEMENTS

BEACON PHARMACEUTICALS LTD. STATEMENT OF FINANCIAL POSITION AS AT JUNE 30, 2013

ASSETS	Notes	30.06.2013	Amount in Taka 30.06.2012
Non-Current Assets:			
Property, Plant & Equipments	3	2,550,094,661	2,698,805,180
Capital Work In Progress	4	880,923	-
Deferred IPO Expense	5	14,203,289	18,937,721
Total Non-Current Assets		2,565,178,873	2,717,742,901
Current Assets:			
Inventories	6	920,497,475	997,651,472
Accounts Receivable	7	157,859,545	125,677,319
Advance, Deposit & Pre-payments	8	440,430,105	428,150,505
Cash & Cash Equivalents	9	7,673,698	7,202,584
Total Current Assets		1,526,460,823	1,558,681,879
Investment in Shares	10	159,980,190	235,000,000
TOTAL ASSETS		4,251,619,886	4,511,424,780
SHAREHOLDERS' EQUITY & LIABILITIES			
Shareholders' Equity:			
Share Capital	11	2,310,000,000	2,310,000,000
Reserve and Surplus	12	336,552,059	354,275,787
Retained Earning	13	126,706,269	99,851,475
Total Shareholders' Equity		2,773,258,328	2,764,127,262
Non-Current Liabilities:			
Long Term Loan	14	776,013,169	850,076,683
Current Liabilities:			
Liabilities for EWF & WPPF	15	14,869,712	13,811,090
Short Term Loan	16	512,496,894	623,092,288
Current Portion of Long Term Loan	17	63,684,240	150,567,892
Share Application Money Refundable	18	4,956,614	5,180,995
Accounts Payables	19	20,837,254	21,020,482
Tax Payable	20	60,362,027	63,994,738
Accrued Expenses	21	24,512,591	19,553,351
VAT Payable	22	629,057	-
Total Current Liabilities		702,348,389	897,220,835
TOTAL SHAREHOLDERS' EQUITY & LIABILITIES		4,251,619,886	4,511,424,780
Net Asset value (NAV) / Share		12.01	11.97
Par Value(Tk.)		10	10

The annexed notes 1 to 34 form an integral part of these financial statements. The financial statements were approved by the Board of Directors on 24.10.2013 and were signed on its behalf by.


Company Secretary


Director


Managing Director

Habib Sarwar & Co.
Chartered Accountants

Dhaka: October 24, 2013

FINANCIAL STATEMENTS

BEACON PHARMACEUTICALS LTD. STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED JUNE 30, 2013

Particulars	Notes	Amount in Taka 2012-2013	Amount in Taka 2011-2012
Turnover (Net of VAT)	23	1,226,906,195	979,436,050
Less: Cost of Goods Sold	24	609,987,995	452,583,791
Gross Profit		616,918,200	526,852,259
Less: Administrative Expenses	25	69,015,856	38,541,999
Less: Marketing, Selling & Distribution Expenses	26	340,510,369	148,522,434
Total Operating Expenses		409,526,225	187,064,433
Operating Profit		207,391,975	339,787,826
Less: Financial Expenses	27	196,958,236	212,120,046
Net Profit after Financial Expenses		10,433,739	127,667,780
Income from Other Sources	28	9,640,884	3,505,401
Net Profit before IPO Expenses		20,074,623	131,173,182
Less: Amortization of Deferred IPO expenses	29	4,734,432	4,734,432
Net Profit before Contribution to WPPF		15,340,191	126,438,750
Less: Contribution to WPPF	30	730,485	6,020,893
Net Profit before Tax		14,609,706	120,417,857
Less: Income Tax	31	5,478,640	45,156,696
Net Profit after Tax		9,131,066	75,261,161
No. of Shares		231,000,000	231,000,000
Earning Per Share		0.04	0.33

The annexed notes 1 to 34 form an integral part of these financial statements. The financial statements were approved by the Board of Directors on 24.10.2013 and were signed on its behalf by.



Company Secretary



Director



Managing Director

Signed as per our report of even date



Habib Sarwar & Co.
Chartered Accountants

Dhaka: October 24, 2013

FINANCIAL STATEMENTS

BEACON PHARMACEUTICALS LTD. STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED JUNE 30, 2013

Amount in Taka

Particulars	Share Capital	Revaluation Reserve	Tax Holiday Reserve	Retained Earning	Total Equity
Balance at the beginning of the year	2,310,000,000	348,772,688	5,503,099	99,851,475	2,764,127,262
Prior year adjustment	-	-	-	-	-
Net Profit transferred from Income Statement	-	-	-	9,131,066	9,131,066
Revaluation Reserve adjustment (Note-32)	-	(17,723,728)	-	17,723,728	-
Transferred to Tax Holiday Reserve	-	-	-	-	-
Investment from Tax Holiday Reserve	-	-	-	-	-
Shares Issued during the year / Payment of Stock Dividend	-	-	-	-	-
Balance at the end of the year	2,310,000,000	331,048,960	5,503,099	126,706,269	2,773,258,328

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED JUNE 30, 2012

Amount in Taka

Particulars	Share Capital	Revaluation Reserve	Tax Holiday Reserve	Retained Earning	Total Equity
Balance at the beginning of the year	2,200,000,000	366,496,416	5,503,099	116,866,586	2,688,866,101
Prior year adjustment	-	-	-	-	-
Net Profit (Loss) transferred to Income Statement	-	-	-	75,261,161	75,261,161
Revaluation Reserve adjustment (Note-27)	-	(17,723,728)	-	17,723,728	-
Transferred to Tax Holiday Reserve	-	-	-	-	-
Investment from Tax Holiday Reserve	-	-	-	-	-
Shares Issued during the year	110,000,000	-	-	(110,000,000)	-
Balance at the end of the year	2,310,000,000	348,772,688	5,503,099	99,851,475	2,764,127,262

The annexed notes 1 to 29 form an integral part of these financial statements. The financial statements were approved by the Board of Directors on 24.10.13 and were signed on its behalf by.


Company Secretary


Director


Managing Director


Habib Sarwar & Co.
Chartered Accountants

Dhaka: October 24, 2013

FINANCIAL STATEMENTS

BEACON PHARMACEUTICALS LTD. STATEMENT OF CASH FLOW FOR THE YEAR ENDED JUNE 30, 2013

Particulars	Amount in Taka 30.06.2013	Amount in Taka 30.06.2012
Cash Flows from Operating Activities:		
Collection against Sales	1,194,723,969	964,534,827
Payment to Creditors	(295,984,793)	(356,300,072)
Other Operating Expenses	(493,412,291)	(243,143,528)
Interest Paid	(196,574,169)	(212,120,046)
Net Cash Generated from Operating Activities	208,752,716	152,971,181
Cash Flows from Investing Activities:		
Acquisition of Property, Plant & Equipments	(21,175,355)	(196,295,211)
Investment in Shares	76,469,810	-
Interest and Other Receipt	8,190,884	3,505,401
Payment to others	-	(22,555,035)
Net Cash Generated from Investing Activities	63,485,339	(215,344,845)
Cash Flows from Financing Activities:		
Capital Received	-	-
Deferred IPO Expense	-	-
Excess Share Application Money Received	-	-
Excess Share Application Money Refund	(224,381)	(111,947)
Long Term Loan Received	-	-
Long Term Loan Refund	(74,063,514)	(54,341,921)
Short Term Loan Refund	(110,595,394)	167,111,622
Current Portion of Long Term Loan	(86,883,652)	(64,645,482)
Net Cash Generated from Financing Activities:	(271,766,941)	48,012,272
Net Cash Increase / (Decrease)	471,114	(14,361,392)
Cash and Bank Balance at the beginning of the year	7,202,584	21,563,976
Cash and Bank Balance at the end of the year	7,673,698	7,202,584
Operating Cash flow per Share	0.90	0.66

The annexed notes 1 to 34 form an integral part of these financial statements. The financial statements were approved by the Board of Directors on 24.10.2013 and were signed on its behalf by.



Company Secretary



Director



Managing Director



Habib Sarwar & Co.
Chartered Accountants

Dhaka: October 24, 2013

BEACON PHARMACEUTICALS LTD.
FIXED ASSETS SCHEDULE
AS AT JUNE 30, 2013

Schedule-A

Particulars	Cost		Rate(%)	Depreciation			Written Down Value as on 30.06.2013
	Balance as on 01.07.2012	Addition During the year		Depreciation as on 01.07.2012	Charged During the year	Depreciation as on 30.06.2013	
Land & Land Development	341,388,689	-	0	-	-	-	341,388,689
Building	587,695,147	4,004,746	5%	81,833,782	29,537,506	111,371,288	480,328,605
Vehicles	54,780,277	5,456,819	20%	24,818,658	11,872,055	36,690,713	23,546,383
Electrical Installations	47,183,635	524,500	10%	12,418,259	4,718,364	17,136,623	30,571,513
Office Equipment	28,260,707	2,897,153	10%	6,660,596	2,956,849	9,617,445	21,540,415
Production Machinery & Equipment	2,099,128,018	6,870,268	15%	349,629,204	117,775,492	467,404,696	1,638,593,590
Furniture & Fixture	21,032,575	540,946	10%	5,303,369	2,144,684	7,448,053	14,125,468
Total	3,179,469,048	20,294,432		480,663,867	169,004,951	649,668,818	2,550,094,662


Note :


- Addition to machineries includes import of machineries for an amount of Tk. 4,874,676 and rest of the amount has been procured locally.
- Other fixed assets have been procured locally.
- There is no contract for capital expenditure to be executed and not provided for in the financial statement.
- Depreciation on assets addition has been charged for six months because most of the assets have been installed in plant after December, 2012 and depreciation charged on an average period of six months. Depreciation was charged on Production Machinery & Equipment @ 15% at a capacity measuring 37.31% assuming that the Machinery was not used for 100% capacity.


Allocation of Depreciation :	Proportion	Amount (Tk.)
Factory Overhead	91%	153,794,505
Administrative Overhead	4%	6,760,198
Selling, Marketing & Distribution Exp.	5%	8,450,248
Total	100%	169,004,951


 Company Secretary

Dhaka: October 24, 2013


 Director


 Managing Director


 Habib Sarwar & Co.
 Chartered Accountants

BEACON PHARMACEUTICALS LTD. NOTES TO THE FINANCIAL STATEMENT FOR THE YEAR ENDED JUNE 30, 2013

1. REPORTING ENTITY AND ITS ACTIVITIES :

a) Legal form of the Entity:

Beacon Pharmaceuticals Ltd. was incorporated in Bangladesh in 2001 under the Companies Act, 1994 as a Private Limited Company and subsequently converted into Public Limited Company on February 25, 2008. It commenced its commercial manufacturing operation in September 2006 and has been started to market its products from October 2006.

The registered office of the company is located at 153-154, Tejgaon I/A, Dhaka - 1208. The industrial units are located in Kathali, Bhaluka, Mymansingh.

b) Nature of Business Activities:

The Company is engaged in manufacturing and marketing of Pharmaceuticals Finished Formulation Products and life saving intravenous (I.V) Fluids, Active Pharmaceuticals Ingredients (APIs), Bio-tech products and genetic engineering products which the company sales in the local markets as well as international markets.

The company also provides contract manufacturing and tool manufacturing services.

2. SIGNIFICANT ACCOUNTING POLICIES:

a). Basis of Measurement of Elements of Financial Statements:

The financial statements have been prepared on the current cost basis and therefore, it takes into consideration the effect of inflation.

b). Components of the Financial Statements:

- i) Statement of Financial Position as at June 30, 2013.
- ii) Statement of Comprehensive Income for the year ended June 30, 2013.
- iii) Statement of Changes in Shareholder's Equity for the year ended June 30, 2013.
- iv) Statement of Cash Flow for the year ended June 30, 2013.
- v) Accounting Policies and Explanatory notes to the Financial Statement for the year ended June 30, 2013.

c) Statement on compliance with local laws:

The financial statements have been prepared in compliance with the requirement of the Companies' Act 1994 and other relevant local laws as applicable.

d) Statement of Compliance of Bangladesh Accounting Standards:

The financial statements have been prepared in accordance with the applicable Bangladesh Accounting Standards (BAS) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) based on International Accounting Standards (IAS) and International Financial Reporting Standards (IFRS).

e) Structure, Content and presentation of Financial Statements:

Being the general purpose of the financial statements, the presentation of these financial statements are in accordance with the guidelines provided by BAS 1: Presentation of the Financial Statements.

NOTES TO THE FINANCIAL STATEMENT

f) Reporting Period:

The financial period of the company covers one year from July 01 to June 30 consistently.

g) Approval of Financial Statements:

The Financial Statements were duly approved by the Board of Directors of the company on October 24, 2013.

h) Currency:

The financial statements are prepared and presented in Bangladesh Taka Currency, which is the company's functional currency. All financial information presented have been rounded off to the nearest Taka except where indicated otherwise.

i) Risk and Uncertainty for use Estimates and Judgments:

The preparation of Financial Statements in conformity with the Bangladesh Accounting Standards requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses and for contingent assets and liabilities that require disclosure, during and at the date of the financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an on going basis revisions of accounting estimates are recognized in the period in which the estimate is revised and in any future periods as required by BAS 8: Accounting policies, changes in accounting estimates and errors.

j) Accrued Expenses and other payables:

Liabilities for the goods and services received have been accounted for.

Payables are non interest bearing and stated at their nominal value.

k) Going Concern:

The company has adequate resources to continue its operation for the foreseeable future. For this reason the directors continue to adopt going concern basis in preparing the financial statement.

l) Financial Instrument:

Non-derivative financial instruments comprise accounts and other receivables, cash and cash equivalents, borrowing and other payables and are shown at transaction cost.

m) Impairment:

In accordance with the provisions of BAS 36: Impairment of assets, the carrying amount of non-financial assets, other than inventories are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the assets recoverable amount is estimated and impairment losses are recognized in profit and loss account. No such indication of impairment has been raised till to date.

n) Segment Reporting and Cash Flow Statement:

No segment reporting is applicable for the company as required by BAS 7: Cash Flow Statement. The cash generating from operating activities has been reported using the Direct Method complying BAS 7: Cash Flow Statement.

o) Transaction with Related Parties:

Beacon Pharmaceuticals Limited (BPL) made a purchase agreement on April 20, 2010 with Beacon Developments Ltd. (BDL) to purchase 25000 sft of office space at Motijheel C/A, Dhaka - 1000 @ Tk. 19,500.00 per sft amounting to Tk. 487,500,000.00

According to the agreement BPL paid an amount of Tk. 218,650,000.00 as advance against purchase of the said

NOTES TO THE FINANCIAL STATEMENT

space but rest of Tk. 268,850,000.00 could not be paid within the stipulated time.

In order to make effective the agreement BPL offered BDL to buy 21,508,000.00 ordinary shares of the company @ Tk. 12.5 per share including 25% premium of the face value to settle the outstanding amount and based on this arrangement the existing vendor's agreement has been revised on July 18, 2011 accordingly.

To rise paid up capital through issue of shares BPL applied to Bangladesh Securities and Exchange Commission (BSEC) on July 26, 2011. After a bunch of correspondences BSEC has finally regret to accord consent to raise paid up capital

As a consequence BDL start repaying the advance received money to BPL. During the period under audit BDL repaid Tk. 123,508,132.00 to BPL and the balance amount will be paid subsequently.

Beacon Pharmaceuticals Limited has invested an amount of Tk. 233,000,000.00 in Beacon Glass Industries Limited for producing, marketing and selling all types of glasses. Beacon Glass Industries Limited was trying to obtain industrial gas line permission from the government since incorporation of the company but Beacon Glass Industries Limited had failed to obtain permeation for the said industrial gas line. Since Beacon Glass Industries Limited is not in a position to start its operation due to non availability of gas, due to such reason it was decided that the amount invested by Beacon Pharmaceuticals Limited to Beacon Glass Industries Limited will be paid back in full gradually. As a consequence Beacon Glass Industries Limited has returned an amount of Tk. 76,469,810.00 to Beacon Pharmaceuticals Limited during the year under audit.

p) Events after the Balance Sheet Date:

In compliance with the requirements of BAS 10: Events after the balance sheet date post balance sheet adjusting events that provide additional information about the company's position as the balance sheet date are reflected in the financial statements and events after the balance sheet date that are not adjusting events are disclosed in the notes when material.

q) Accounting Policies for significant Items:

The accounting policies in respect of materiality of items of financial statement set below have been applied consistently to all periods presented in these financial statements.

q.1) Revenue Recognition Policy:

In compliance with requirements of BAS 18: Revenue, revenue from receipts from customers against sales is recognized when products are dispatched to customers, that is, when the significant risk and rewards of ownership have been transferred to the buyer recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably and there is no continuing management involvement with the goods.

q.2. Property, Plant and Equipment:

q.2.1. Recognition and Measurement:

Property, plant and equipment are capitalized at cost less accumulated depreciation in compliance with the requirements of BAS 16: Property, Plant and Equipment. The cost of acquisition of an asset comprises its purchase price and any directly attributable cost of bringing the assets to its working condition for its intended use inclusive of inward freight, duties and non-refunded taxes.

q.2.2 Depreciation on Property, plant & Equipment:

Depreciation is provided to amortize the cost of the assets after commissioning, over the period of their expected useful lives, in accordance with the provision of BAS 16: Property, Plant and Equipment. Depreciation is provided for the period in use of the assets.

NOTES TO THE FINANCIAL STATEMENT

q.3 Inventories:

Inventories are carried at the lower of cost and net realizable value as prescribed by BAS 2: Inventories. Cost determined on weighted average cost basis. The cost of inventories comprises of expenditure in the normal course of business in bringing the inventories to their present location and condition. Net realizable value is based on estimated selling price less any further costs expected to be incurred to make the sale. Cost formula used for inventory valuation.

Nature of Inventories	Cost Formula
Raw Materials	Weighted Average Cost
Packing Materials	Weighted Average Cost
WIP	Actual Cost
Finished Goods	Actual Cost
Others	Actual Cost

q.4 Cash and Cash Equivalents:

Cash and Cash equivalents includes cash in hand and with banks on current and deposit accounts which are held and available for use by the company without any restriction. There is insignificant risk of change in value of the same.

q.5 Income Tax Expenses:

Income tax expense comprises current tax. Income tax expense is recognized in profit and loss account and accounted for in accordance with the requirements of BAS 12: Income Tax.

q.6 Tax Holiday Reserve:

The Tax holiday period of the company has expired on September 30, 2010 and company has created tax holiday reserve @ 10% from its profit for the 1st quarter ended September 30, 2010 as required by the Income Tax Ordinance 1984.

q.7 Foreign Currency Transaction:

Foreign currency transactions are recorded at the applicable rates of exchange prevailing at the transaction date in accordance with the provisions of BAS 21: The effects of changes in foreign currency rate. The monetary assets and liabilities, If any, denominated in foreign currencies at the balance sheet date are translated at the applicable rates of exchanges prevailing on that date.

NOTES TO THE FINANCIAL STATEMENT

Notes	Particulars	Amount in Taka	Amount in Taka
		30.06.2013	30.06.2012
3.00	PROPERTY, PLANT & EQUIPMENT: Tk. 2,550,094,661		
	Balance as on 01.07.2012	3,179,469,048	2,983,173,837
	Addition during the year	20,294,432	196,295,211
		3,199,763,480	3,179,469,048
	Less: Disposal during the year	-	-
	Depreciable Value as on 30.06.2013	3,199,763,480	3,179,469,048
	Accumulated Depreciation as at 01.07. 2012	480,663,868	314,131,068
	Depreciation charged during the year	169,004,951	166,532,800
		649,668,819	480,663,868
	Less: Accumulated depreciation on disposal of assets	-	-
	Accumulated Depreciation as on 30.06.2013	649,668,819	480,663,868
	Written Down Value as on 30.06.2013	2,550,094,661	2,698,805,180
	Details has been shown in Schedule -A		
4.00	Capital Work In Progress: Tk. 880,923	880,923	-
5.00	DEFERRED IPO EXPENSES: Tk. 14,203,289		
	Balance as on 01.07.2012	18,937,721	23,672,153
	Less: Amortization during the year	4,734,432	4,734,432
	Balance as on 30.06.2013	14,203,289	18,937,721
	These expenses comprised all sorts of expenditures related to Initial Public Offering of the Company. This expenditure has been deferred and it will be amortized by five years starting from 1st July, 2011.		
6.00	INVENTORIES: Tk. 920,497,475		
	Raw Materials	302,056,099	266,033,528
	Work-in-Process (Note-20.02)	23,090,823	38,679,311
	Finished Goods (Note-20.04)	480,030,127	556,542,376
	Packing Materials	60,631,646	71,455,565
	Literature & Promotional Materials	19,972,199	18,769,948
	Laboratory Chemicals	23,491,726	22,752,484
	Stock of Stationery	5,747,779	5,505,298
	Spares & Accessories	5,477,076	17,912,962
	Balance as on 30.06.2013	920,497,475	997,651,472

Inventories are carried at the lower of cost and net realizable value as prescribed by BAS 2. Cost of inventories are determined on weighted average cost basis. The said inventories are mortgaged with Janata Bank Ltd., Corporate Branch.

Physical verification of inventories was carried out by inventory team consisting of management staff. The inventories are collateralized against Short Term Loan.

NOTES TO THE FINANCIAL STATEMENT

Notes	Particulars	Amount in Taka	Amount in Taka
		30.06.2013	30.06.2012
7.00	ACCOUNTS RECEIVABLE: Tk. 157,859,545		
	Barishal Sales Centre	4,443,867	3,211,861
	Bogra Sales Centre	1,948,223	2,183,232
	Chittagong Sales Centre	8,659,563	7,575,794
	Chowmohony Sales Centre	6,634,524	4,432,761
	Comilla Sales Centre	6,431,906	4,102,614
	Dhaka Sales Centre	70,062,366	70,227,584
	Faridpur Sales Centre	1,997,193	2,281,751
	Khulna Sales Centre	2,306,775	2,248,494
	Mymensingh Sales Centre	5,837,993	4,872,636
	Narayangonj Sales Centre	6,716,416	6,178,862
	Rajshahi Sales Centre	5,273,400	4,173,072
	Rangpur Sales Centre	4,152,623	4,480,180
	Sylhet Sales Centre	4,554,161	2,421,788
	Dhaka Sales Centre - Palton	2,578,454	3,267,582
	Contact Manufacturing	2,890,393	4,019,107
	Moulavi Bazar Sales Center	1,275,911	-
	Cox's Bazar Sales Center	1,280,924	-
	Dhaka Sales Center-Mohd. Pur Kakril	20,814,853	-
	Balance as on 30.06.2013	157,859,545	125,677,319

The above receivables are considered good and secured by the management.

The above amount is receivable from customers against credit sales.

No amount was due from the Directors, Managing Director and other officers of the Company and any of them or jointly with any other person.

The Accounts Receivables have no securities except their personal securities.

NOTES TO THE FINANCIAL STATEMENT

Notes	Particulars	Amount in Taka	Amount in Taka
		30.06.2013	30.06.2012
8.00	ADVANCE, DEPOSIT & PREPAYMENTS: Tk. 440,430,105		
	Advance to Creditors:		
	Advance VAT	11,215,394	418,742
	Advance of Raw Materials Suppliers	-	356,366
	Advance to Printing and Packing Material Suppliers	840,237	237,716
	Advance to Computer Accessories Suppliers	-	211,568
	Advance to QC Chemical Suppliers	-	7,160,536
	Advance to PVC & Foil Suppliers	-	7,003,555
	Advance against office space purchase	95,141,868	218,650,000
	Advance to Clearing & Forwarding Agent	4,530,450	8,452,299
	Advance to other Parties	47,016,190	22,509,654
	Advance to Plastic Item suppliers	-	97,966
	Advance to Glass Items Suppliers	-	35,602
	Advance to Machinery & Equipment Suppliers	-	595,549
	Advance to vehicles suppliers	-	2,577,500
	Advance to Furniture Suppliers	-	192,673
	Advance to construction materials suppliers	104,110,660	1,968,884
	Advance to advertising agencies	-	2,396,620
	Advance to the promotional suppliers	-	1,672,001
	Advance to travel agencies	-	953,259
	SubTotal	262,854,799	275,490,490
	Advance to Employees:		
	Salary	212,052	-
	Traveling Expenses	953,259	-
	Motor Cycle	(5,068,000)	-
	Impress Money	281,731	256,231
	Against Marketing Expense	710,218	673,936
	Other	14,979,880	-
	Sub-Total	12,069,140	930,167
	L/C Margin, Earnest Money & Security Deposit:		
	L/C Margin and Immatured L/Cs	157,184,196	147,241,325
	Earnest Money to Tender	3,153,537	1,150,203
	Security Deposit - Titas Gas	3,518,378	3,252,180
	Security Deposit - Electricity	56,140	56,140
	Security Deposit - T & T	30,000	30,000
	Security Deposit - Other	1,563,915	-
	Sub-Total	165,506,166	151,729,848
	Grand Total	440,430,105	428,150,505

There is no aggregate amount due from Directors.

There is no claim against the Company, which can be acknowledged as bad debt.

No amount is due by the associated undertakings.

NOTES TO THE FINANCIAL STATEMENT

Notes	Particulars	Amount in Taka	Amount in Taka
		30.06.2013	30.06.2012
9.00	CASH & CASH EQUIVALANTS: Tk. 7,673,698		
9.01	Cash in hand (Including all depots)	3,197,832	2,564,351
	Balance as on 30.06.2013	3,197,832	2,564,351
9.02	Cash at Bank:		
	HSBC - CD A/C. No. 001143379011	96,404	102,324
	First Security Islami Bank Ltd. - CD A/C. No. 1110001246	28,367	6,636,845
	Janata Bank Ltd. CD A/C. No. - 1014203	(3,504,294)	(934,567)
	Janata Bank Ltd. CD A/C. No. - 001016781	4,277	6,927
	Shahjalal Islami Bank Ltd. AWA A/C. No. 10078	21,563	19,709
	The City Bank Ltd. CD A/C. No. 392001, Barishal Sales Centre	-	1,434
	The City Bank Ltd. CD A/C. No. 41568001, Bogra Sales Centre	-	10,554
	The City Bank Ltd. CD A/C. No. 1101040957001, Chittagong Sales Centre	-	184
	The City Bank Ltd. CD A/C. No. 1102358521001, Dinajpur Sales Centre	5,696	5,696
	The City Bank Ltd. CD A/C. No. 1101040964001, Khulna Sales Centre	-	11,427
	The City Bank Ltd. CD A/C. No. 1102351563001, Mymensingh Sales Centre	-	1,005
	The City Bank Ltd. CD A/C. No. 11026990, Narayanganj Sales Centre	727	1,417
	The City Bank Ltd. CD A/C. No. 1102234617001, Rangpur Sales Centre	-	3,970
	The City Bank Ltd. CD A/C. No. 1102193550001, Sylhet Sales Centre	28,188	28,988
	Standard Chartered Bank, CD A/C. No. 02535409901	927,501	2,771,220
	ICB Islami Bank Ltd. Principal Br., CD A/C. No. 1000200001361	37,220	39,820
	Dutch Bangla Bank Ltd. CD A/C. No. 0105110000016107	(5,485,414)	(628,149)
	Dutch Bangla Bank Ltd. STD A/C. No. 010511000001641	2,758,104	(12,502,954)
	Eastern Bank Ltd. STD A/C. No. 1011230000071 (IPO Proceeds - BDT)	1,700,328	1,762,088
	Eastern Bank Ltd. STD A/C. No. 1013150120364 (IPO Proceeds - Euro)	586,660	632,347
	Eastern Bank Ltd. STD A/C. No. 1013110120344 (IPO Proceeds - USD)	3,736,694	4,111,628
	Eastern Bank Ltd. STD A/C. No. 1013120120354 (IPO Proceeds - GBP)	1,125,215	1,256,350
	Rupali Bank Ltd., Local Office Branch, Motijheel C/A., Dhaka. CD A/C. 89649	3,910	8,000
	Sonali Bank Ltd., Dilkusha Corporate Branch, Motijheel, Dhaka. CD A/C. 33028459	8,275	9,425
	Janata Bank Ltd., Bhaluka Branch. STD A/C. 0000131	1,400,294	1,282,546
	Janata Bank Ltd., Sundry Deposit A/C. 70104001	521,460	-
	Janata Bank Ltd. FC A/C. 402000449	60,505	-
	Bank Asia Ltd. CD A/C. 004433010401	8,175	-
	Social Islami Bank Ltd. Cd A/C. No. 21330052331	6,952	-
	The City Bank Ltd. CD A/C. No. 1101029459001	1,141	-
	Dutch Bangla Bank Ltd., CD A/C No. 105.110.28382	397,919	-
	Balance as on 30.06.2013	4,475,866	4,638,233
	Grand Total	7,673,698	7,202,584

Since our audit was post dated we could not physically verify the cash in hand balance at the year ended. The company has cash in hand balance with its head office and sales centers in different location. The management has issued cash custody certificate confirming the balance held by them on the closing date.

"The company has 31 Bank accounts and we have received bank statement of all the bank accounts which agreed with the book balance. We have received bank reconciliation statements of few bank accounts which agreed with the book balance after reconciliation. "

NOTES TO THE FINANCIAL STATEMENT

Notes	Particulars	Amount in Taka	Amount in Taka
		30.06.2013	30.06.2012

10.00 **INVESTMENT IN SHARES: Tk. 159,980,190**

Investment in Shares of Active Fine Chemicals Ltd.	3,450,000	2,000,000
Investment in Beacon Glass Industries Ltd.	156,530,190	233,000,000
Balance as on 30.06.2013	159,980,190	235,000,000

The Company has purchased 200,000 ordinary shares of Tk.10 each of Active Fine Chemicals Ltd. amounting to Tk.2,000,000 which is traded in DSE & CSE on November 23, 2010. Subsequently the Company has received stock dividend of 145,000 shares.

11.00 **SHARE CAPITAL: Tk. 2,310,000,000**

Authorized Capital:

300,000,000 ordinary shares of Tk. 10 each	3,000,000,000	3,000,000,000
--	---------------	---------------

Issued, Subscribed and Paid-up Capital:

231,000,000 ordinary shares of Tk. 10 each	2,310,000,000	2,310,000,000
--	---------------	---------------

Shareholding Composition:

Shareholders Group	No. of shares held	No. of Shareholders	% of total shares
1. Sponsors & Directors	69,312,000	7	30.00
2. Corporate Bodies	43,637,685	32	18.89
3. General Investors	118,050,315	35,214	51.11
Total	231,000,000	35,253	100

12.00 **RESERVE & SURPLUS: Tk. 336,552,059**

Revaluation Reserve (Note-12.01)	331,048,960	348,772,688
Tax Holiday Reserve @10% of Net Profit	5,503,099	5,503,099
Balance as on 30.06.2013	336,552,059	354,275,787

12.01 **REVALUATION RESERVE: Tk. 331,048,960**

Revaluation Reserve has been created out by the amount of revaluation surplus of Fixed Assets. Details are shown below:

Particulars	Revaluation Surplus as on 01.07.2012	Depreciation adjustment	Revaluation Reserve
Land & Land Development	168,084,972	-	168,084,972
Building	18,223,294	1,072,484	17,150,810
Vehicles	3,819,602	1,917,791	1,901,811
Electrical Installation	5,194,307	742,928	4,451,379
Office Equipments	(7,787,386)	-	(7,787,386)
Machineries	167,769,709	13,990,525	153,779,184
Furniture & Fixtures	(6,531,810)	-	(6,531,810)
Total	348,772,688	17,723,728	331,048,960

NOTES TO THE FINANCIAL STATEMENT

Notes	Particulars	Amount in Taka	Amount in Taka
		30.06.2013	30.06.2012
13.00	Retained Earning: Tk. 126,706,269		
	Balance as on 01.07.2012	99,851,475	116,866,586
	Add: Net Profit during the year	9,131,066	75,261,161
	Revaluation Reserve adjustment	17,723,728	17,723,728
	Share Issued During the Year (Stock Dividend)	-	(110,000,000)
	Balance as on 30.06.2013	126,706,269	99,851,475
14.00	LONG TERM LOAN: Tk. 776,013,169		
	Janata Bank Ltd.	113,975,087	134,164,367
	Agrani Bank Ltd.	120,191,793	142,684,666
	Social Islami Bank Ltd.	-	81,493,817
	The City Bank Ltd.	-	192,613,284
	Dhaka Bank Ltd.	-	42,387,020
	Sonali Bank Ltd.	189,734,566	192,954,780
	Shahajalal Islami Bank Ltd.	-	24,942,171
	Southeast Bank Ltd.	-	38,836,578
	Janata Bank Ltd. (Takeover)	352,111,723	-
	Balance as on 30.06.2013	776,013,169	850,076,683
<p>In order to reduce banking hassle and comparatively high interest of five private Banks namely Social Islami Bank Ltd., The City Bank Ltd., Dhaka Bank Ltd., Shahajalal Islami Bank Ltd. and Southeast Bank Ltd. those are the consortium partners of the project loan, Beacon Pharmaceuticals Ltd. proposed Janata Bank Ltd. Janata Bank Bhabon Corporate Branch, Mothijhel C/A., Dhaka-1000 to take over the total liabilities of these Banks and Janata Bank Ltd. has finally taken over the total liabilities of those Banks.</p> <p>At the time of taking over, the total liabilities of those bank was Tk. 368,621,000.00.</p>			
15.00	LIABILITY FOR EWF & WPPF: Tk. 14,869,712		
	Employees Welfare Fund (EWF) - (Note 15.01)	1,219,898	891,762
	Workers Profit Participation Fund (WPPF) - (Note 15.02)	13,649,814	12,919,329
	Balance as on 30.06.2013	14,869,712	13,811,090
15.01	Employees Welfare Fund (EWF): Tk. 1,219,898		
	Balance as on 01.07.2012	891,762	731,401
	Add: Contribution during the year	485,557	379,647
	Total Contribution	1,377,319	1,111,048
	Less: Paid to the employees	157,421	219,286
	Balance as on 30.06.2013	1,219,898	891,762

NOTES TO THE FINANCIAL STATEMENT

Notes	Particulars	Amount in Taka	Amount in Taka
		30.06.2013	30.06.2012
15.02	Workers Profit Participation Fund: Tk. 13,649,814		
	Balance as on 01.07.2012	12,919,329	6,898,436
	Add: Contribution during the period	730,485	6,020,893
	Total Contribution	13,649,814	12,919,329
	Less: Paid to the employees	-	-
	Balance as on 30.06.2013	13,649,814	12,919,329
16.00	SHORT TERM LOAN: Tk. 512,496,894		
	PAD - First Security Bank Ltd., Gulshan Branch, Dhaka	35,148,753	50,648,753
	PAD - Janata Bank Ltd.	35,783,462	67,677,580
	CC (Hypo)- Janata Bank Ltd., Corporate Bhaban Branch, Motijheel, Dhaka	415,206,314	467,295,904
	BM(Hypo)-ICB Islami Bank Ltd., Principal Branch	26,358,365	37,470,051
	Balance as on 30.06.2013	512,496,894	623,092,288
	* Short term loan was taken for meeting the requirement of working capital of the Company.		
17.00	CURRENT PORTION OF LONG TERM LOAN: Tk. 63,684,240		
	Janata Bank Ltd.	12,062,295	18,132,000
	Agrani Bank Ltd.	26,542,230	55,878,378
	Social Islami Bank Ltd.	-	11,000,000
	The City Bank Ltd.	-	18,130,000
	Dhaka Bank Ltd.	-	5,600,000
	Sonali Bank Ltd.	-	17,098,000
	Shahajalal Islami Bank Ltd.	-	18,869,514
	Southeast Bank Ltd.	-	5,860,000
	Janata Bank Ltd. (Takeover)	25,079,715	-
	Balance as on 30.06.2013	63,684,240	150,567,892
18.00	SHARE APPLICATION MONEY REFUNDABLE: Tk. 4,956,614	4,956,614	5,180,995

NOTES TO THE FINANCIAL STATEMENT

Notes	Particulars	Amount in Taka	Amount in Taka
		30.06.2013	30.06.2012
19.00	ACCOUNTS PAYABLE: Tk. 20,837,254		
	Against Raw Materials	1,813,719	971,443
	Against Laboratory Chemicals	2,079,462	562,308
	Against Computer	191,027	116,167
	Against Plastic Items	731,986	110,407
	Against Machinery & Equipment	1,362,684	522,196
	Against Printing & Packaging Materials	7,877,448	7,921,026
	Against PVC & Foil suppliers	414,592	24,000
	Against to Clearing & Forwarding Agent	1,373,485	2,869,435
	Against maintenance & Service	25,000	25,000
	Against vehicles suppliers	(871,215)	639,085
	Against to construction materials suppliers	3,300,681	4,273,610
	Against to advertising agencies	397,202	760,490
	Against to the promotional suppliers	(1,462,220)	1,626,577
	Against to travel agencies	29,200	461,698
	Against Transport & Courier	200,688	100,851
	Against Fuel Supplier	27,260	36,190
	Against Glass Item - Suppliers	(565,809)	-
	Against Furniture & Fixture	201,939	-
	Against Insurance Premium	1,909,117	-
	Against Misc. Suppliers	1,144,293	-
	Balance as on 30.06.2013	20,180,539	21,020,482
19.01	Depot Expenses Payable: Tk. 656,715		
	Rangpur Depot	(74,288)	-
	Bogra Depot	(16,180)	-
	Rajshahi Depot	(30,636)	-
	Khulna Depot	41,516	-
	Barisal Depot	106,568	-
	Faridpur Depot	30,351	-
	Mymensingh Depot	42,816	-
	Narayangonj Depot	125,796	-
	Comilla Depot	92,793	-
	Sylhet Depot	16,814	-
	Maizdee Depot	78,030	-
	Chittagong Depot	18,464	-
	Depot Expenses Payable-CDC	48,374	-
	Dhaka (Mohammadpur) Depot	239,022	-
	Narayangonj / Kakrail Depot	(62,725)	-
	Balance as on 30.06.2013	656,715	-
	Grand Total	20,837,254	21,020,482

Accounts payable for supply of raw materials, packing materials & other promotionals are the regular suppliers of the Company and the amount are due on account.

We were informed by the management that most of the bills are paid within 60 days.

NOTES TO THE FINANCIAL STATEMENT

Notes	Particulars	Amount in Taka	Amount in Taka
		30.06.2013	30.06.2012
20.00	TAX PAYABLE: Tk. 60,362,027		
	Income Tax Payable for current year	58,757,879	63,719,475
	TDS from Salary & Allowance	1,375,067	223,741
	TDS from Gas Bills	84,511	41,521
	TDS From Audit Fee	10,000	10,000
	TDS From Trade Creditors	65,652	-
	TDS From Office Rent	68,918	-
	Balance as on 30.06.2013	60,362,027	63,994,738
21.00	ACCRUED EXPENSES: Tk. 24,512,591		
	Audit Fees (Less TDS)	100,000	75,000
	Electric Bill	38,927	-
	Salary & Allowance Payable	23,317,860	18,412,407
	Gas Bills	1,052,897	1,055,534
	Telephone Bill	2,907	10,410
	Balance as on 30.06.2013	24,512,591	19,553,351
22.00	VAT Payable: Tk. 629,057		
	Trade Creditors	135,000	-
	House rent	83,147	-
	Audit Fees	15,000	-
	Advertisement & Publicity	395,910	-
	Balance as on 30.06.2013	629,057	-
23.00	Turnover: Tk. 1,226,906,195		
	Total Sales	1,465,790,709	1,135,949,483
	Less: Sales Discount	105,283,413	59,989,888
		1,360,507,296	1,075,959,595
	Less: Value Added Tax	133,601,101	96,523,545
	Turnover (Net of discount and VAT)	1,226,906,195	979,436,050

During the year we observed that the company's foreign sales is Tk. 18,236,510 and local sales Tk. 1,447,554,199

NOTES TO THE FINANCIAL STATEMENT

Notes	Particulars	Amount in Taka	Amount in Taka
		30.06.2013	30.06.2012
24.00	COST OF GOODS SOLD: Tk. 609,987,995		
	Materials Consumed (Note-24.01)	269,946,198	339,479,615
	Add: Opening Work-in-Process	38,679,311	36,835,756
	Total Work-in-Process	308,625,509	376,315,371
	Less: Closing Work-in-Process (Note-24.02)	23,090,823	38,679,311
	Total Consumption	285,534,686	337,636,060
	Factory Overhead (Note-24.03)	247,941,060	222,611,895
	Cost of Production	533,475,746	560,247,955
	Add: Opening Finished Goods	556,542,376	448,878,212
	Finished Goods available for Sale	1,090,018,122	1,009,126,167
	Less: Closing Finished Goods (Note-24.04)	480,030,127	556,542,376
	Cost of Goods Sold	609,987,995	452,583,791
24.01	MATERIALS CONSUMED: Tk. 269,946,198		
	Opening Inventory (Raw & Packing material)	337,489,093	318,872,342
	Add: Purchase	295,144,850	358,096,366
	Materials available for use	632,633,943	676,968,708
	Less: Closing Inventory (Raw & Packing material)	362,687,745	337,489,093
	Total	269,946,198	339,479,615
24.02	CLOSING WORK- IN- PROCESS: Tk. 23,090,823	23,090,823	38,679,311
24.03	FACTORY OVERHEAD: Tk. 247,941,060		
	Salaries & Allowances	45,941,679	41,517,679
	Travelling & Conveyance	304,332	404,941
	Canteen Fooding Expenses	-	3,875,065
	Entertainment	800,279	707,180
	Welfare & Recreation	5,500,588	756,013
	Uniform & Laveries	-	215,362
	Transportation	2,486,074	1,887,906
	Telephone & Postage	1,258,695	1,158,767
	Utilities	10,324,181	10,019,631
	Fees & Taxes	344,331	215,543
	Books & Periodicals	3,858	16,471
	Printing & Stationery	2,488,671	2,301,785
	Handling & Carrying Expense	5,600	76,600
	Research & Development Expense	3,987,595	2,591,794
	Repairs & Maintenance	19,005,478	5,318,106
	Other Expense	67,701	4,204
	Insurance	1,627,493	
	Depreciation	153,794,505	151,544,848
	Total	247,941,060	222,611,895

Salaries and allowances increased due to the increase of the numbers of employees and increment as well.
 Telephone & Postage has been increased due to the increase of number of employees to whom mobile phones have been given.
 Transport has been increased due to the increase of number of hired transport for increasing of employees.

NOTES TO THE FINANCIAL STATEMENT

Notes	Particulars	Amount in Taka	Amount in Taka
		30.06.2013	30.06.2012
24.04	CLOSING FINISHED GOODS :Tk. 480,030,127	480,030,127	556,542,376
25.00	ADMINISTRATIVE EXPENSES: Tk. 69,015,856		
	Salaries & Allowances	23,063,468	17,774,976
	Travelling & Conveyance	1,995,466	1,930,650
	Entertainment	16,557,158	1,115,200
	Canteen Fooding Expense	-	265,935
	Welfare & Recreation	1,179,219	354,996
	Office Rent	1,260,000	1,260,000
	Office Transport	1,536,288	820,638
	Utilities	678,153	673,077
	Telephone & Postage	1,802,112	785,913
	Fees & Taxes	667,427	1,356,674
	Books, News Paper & Periodicals	12,754	23,135
	Printing & Stationery	1,468,487	907,509
	Audit Fee	125,000	100,000
	Legal & Consultancy Fee	519,700	475,000
	Legal & Other Expense	-	155,085
	Insurance Premium	1,422,300	1,165,229
	Bank Charge & Other Expense	737,731	911,978
	Renewal & Documentation Expense	1,669,746	636,843
	Handling & Carrying Expense	45,300	30,245
	Repairs & Maintenance	735,024	225,366
	Advertisement & Publicity	3,379,635	787,247
	Training Expense	132,680	41,109
	Misc. Expense	3,268,010	83,882
	Depreciation	6,760,198	6,661,312
	Total	69,015,856	38,541,999

Salaries and allowances increased due to the increase of the numbers of employees and increment as well.

NOTES TO THE FINANCIAL STATEMENT

Notes	Particulars	Amount in Taka	Amount in Taka
		30.06.2013	30.06.2012
26.00	MARKETING, SELLING & DISTRIBUTION EXPENSES: Tk. 340,510,369		
	Salaries & Allowances	195,215,539	80,742,448
	Travelling & Conveyance	11,184,340	4,475,492
	Entertainment	8,779,975	1,472,641
	Welfare & Recreation	2,527,513	591,571
	Depot Rent	4,017,007	4,233,275
	Transportation	1,231,603	1,251,718
	Utilities	877,502	598,005
	Telephone & Postage	5,172,913	1,251,142
	Fees & Taxes	1,477,889	761,756
	Books, News Paper & Periodicals	16,960	10,650
	Printing & Stationery	7,276,482	3,811,749
	Bank Charges	436,079	330,634
	Market Research & New Products	4,363,918	3,072,880
	Training Expense	1,983,689	1,547,337
	Promotional Expense	50,492,147	24,574,406
	Conference, Fair & product Launch	7,738,620	6,036,314
	Delivery Expense	6,964,135	2,970,326
	Advertisement & Publicity	708,039	898,826
	Repairs & Maintenance	551,038	406,281
	Misc. Expense	493,961	190,032
	Insurance Premium	1,531,417	632,770
	Corporate Social Responsibilities	25,200	137,450
	Handling & Carrying	520,033	198,091
	Depreciation	8,450,248	8,326,640
	Field Force Market Coverage Expenses	18,474,124	-
	Total	340,510,369	148,522,434

NOTES TO THE FINANCIAL STATEMENT

Notes	Particulars	Amount in Taka	Amount in Taka
		30.06.2013	30.06.2012
27.00	FINANCIAL EXPENSES: Tk. 196,958,236		
	Interest on Consortium Loan :		
	Janata Bank Ltd.	24,428,453	15,696,238
	Agrani Bank Ltd.	18,710,105	25,314,785
	Social Islami Bank Ltd.	12,598,301	14,428,523
	The City Bank Ltd.	24,253,711	33,382,730
	Dhaka Bank Ltd.	4,623,197	6,466,429
	Sonali Bank Ltd.	28,971,786	28,631,121
	Shahajalal Islami Bank Ltd.	7,014,568	6,936,588
	Southeast Bank Ltd.	5,273,592	6,863,644
	Sub-Total	125,873,713	137,720,058
	Interest on Short Term Loan:		
	LTR - First Security Bank Ltd., Gulshan Branch, Dhaka	2,375,000	-
	CC(Hypo) - Janata Bank Ltd., Corporate Bhaban, Motijheel	65,387,740	68,191,071
	BM(Hypo)- ICB Islami Bank Ltd., Principal Branch.	2,937,716	6,208,917
	Bank Charge Other	384,067	-
	Sub-Total	71,084,523	74,399,988
	Grand Total	196,958,236	212,120,046
28.00	INCOME FROM OTHER SOURCES: Tk. 9,640,884		
	Interest Received from Bank (From IPO Application Money Deposit)	271,816	85,994
	Received from Scrap Sales	7,919,068	3,419,407
	Dividend Income (Stock Dividend)	1,450,000	-
	Total	9,640,884	3,505,401
29.00	AMORTIZATION OF DEFERRED IPO EXPENSES :	4,734,432	4,734,432
30.00	CONTRIBUTION TO WORKERS PROFIT PARTICIPATION FUND: Tk. 730,485		
	This represents 5% of net profit before tax after charging contribution as per provision of the Bangladesh Labor Law 2006 .		
31.00	TAX LIABILITY ON CURRENT PROFIT: 58,757,879		
	Tax Liability on Previous Years	63,719,475	26,367,246
	Tax on current Profit	5,478,640	45,156,696
		69,198,115	71,523,942
	Less: AIT Adjustment	10,440,236	7,804,467
	Total	58,757,879	63,719,475

NOTES TO THE FINANCIAL STATEMENT

Notes	Particulars	Amount in Taka	Amount in Taka
		30.06.2013	30.06.2012

32.00 REVALUATION RESERVE ADJUSTMENT: Tk. 17,723,728

Particulars	Revaluation Surplus	Useful Life (Years)	Depreciation on Revaluation Surplus
Land & Land Development	168,084,972	-	-
Building	19,295,778	20	1,072,484
Vehicles	5,737,393	5	1,917,791
Electrical Installation	5,937,235	10	742,928
Office Equipments	(7,787,386)	10	-
Machineries	181,760,234	15	13,990,525
Furniture & Fixture	(6,531,810)	10	-
Total	366,496,416		17,723,728

33.00 **General Comments & Observations:**

33.01 All shares have been fully called and paid up.

33.02 There was no preference shares issued by the company.

33.03 There was no Bank guarantee issued by the company on behalf of the directors or the company itself except bank loan.

33.04 The company has not incurred any foreign currency against royalties, technical fees etc.

33.05 There was no some for which the company is contingently liable as on June 30, 2013.

33.06 Auditors are paid only statutory audit fee approved by the shareholders in the last Annual General Meeting.

33.07 There was no foreign exchange remitted to the relevant shareholders during the year under audit.

33.08 **Basic Earnings Per Shares (EPS)-Disclosure under IAS 33:**

Basic Earnings Per Shares (EPS):	Net Profit After Tax	
	Weighted average numbers of shares outstanding during the year 2012-2013	
Basic Earnings Per Shares (EPS):	9,131,066	
	231,000,000	
Basic Earnings Per Shares (EPS):	0.04	

NOTES TO THE FINANCIAL STATEMENT

Notes	Particulars	Amount in Taka	Amount in Taka
		30.06.2013	30.06.2012

33.09 There has been no claim against the company not acknowledged as debts at the date of The Statement of Financial Position.

33.10 No amount of money was expended by the company for compensating any member of the board of special service rendered.

33.11 **Total number of employees drawing remuneration are as follows:**

Salary Range	No. of Employees.
No. of employees Having Salary Between Tk.4,000 to Tk. 5,000	255
No. of employees Having Salary Between Tk.5,000 to Tk. 10,000	534
No. of employees Having Salary Between Tk.10,000 to Tk. 15,000	323
No. of employees Having Salary Between Tk.15,000 to Tk. 25,000	145
No. of employees Having Salary Between Tk.25,000 to Tk. 50,000	63
No. of employees Having Salary Between Tk. 50,000 and Above	41
Total	1361

33.12 **RELATED PARTY TRANSACTION: Tk. 218,650,000**

A Investment in Office Space Purchase

"Beacon Pharmaceuticals Limited (BPL) made a purchase agreement on April 20, 2010 with Beacon Developments Ltd. (BDL) to purchase 25000 sft of office space at Motijheel C/A, Dhaka – 1,000 @ Tk. 19,500.00 per sft amounting to Tk. 487,500,000.00

According to the agreement BPL paid an amount of Tk. 218,650,000.00 as advance against purchase of the said space but rest of Tk. 268,850,000.00 could not be paid within the stipulated time.

In order to make effective the agreement BPL offered BDL to buy 21,508,000.00 ordinary shares of the company @ Tk. 12.5 per share including 25% premium of the face value to settle the outstanding amount and based on this arrangement the existing vendors agreement has been revised on July 18, 2011 accordingly.

To raise paid up capital through issue of shares BPL applied to Bangladesh Securities and Exchange Commission (BSEC) on July 26, 2011. After a bunch of correspondences BSEC has finally regret to accord consent to raise paid up capital.

As a consequence BDL start repaying the advance received money to BPL. During the period under audit BDL repaid Tk. 123,508,132.00 to BPL and the balance amount will be paid subsequently."

B Investment in Beacon Glass Industry Ltd.

Beacon Pharmaceuticals Limited has invested an amount of Tk. 233,000,000.00 in Beacon Glass Industries Limited for producing, marketing and selling all types of glasses. Beacon Glass Industries Limited was trying to obtain industrial gas line permission from the government since incorporation of the company but Beacon Glass Industries Limited had failed to obtain permeation for the said industrial gas line. Since Beacon Glass Industries Limited is not in a position to start its operation due to non availability of gas, due to such reason it was decided that the amount invested by Beacon Pharmaceuticals Limited to Beacon Glass Industries Limited will be paid back in full gradually. As a consequence Beacon Glass Industries Limited has returned an amount of Tk. 76,469,810.00 to Beacon Pharmaceuticals Limited during the year under audit.

34.00 **EVENTS AFTER THE STATEMENT OF FINANCIAL POSITION:**

There is no significant event other than normal activities between the financial year closing date and financial signing date.

Production Line



Production Team



New Products launching in the year

BEVASTIM

Bevacizumab 100 mg Injection

Unique Antiangiogenic Drug in
Non - Squamous NSCLC

xifos

Ifosfamide 1 gm & 2 gm Injection

Secure & Reliable Partner

Trastunix

Trastuzumab INN 440 mg Injection

A Revolutionary Treatment Option for
HER2+ cancers

Rituxim

Rituximab 100 mg Injection

The new treatment paradigm for NHL & CLL

Xevirol

Everolimus INN 5 mg & 10 mg tablet

The Golden Key to Overcome Hormonal Resistance

Sunitix

Sunitinib 50 mg Capsule

Prolonging survival, reducing toxicity

Soranix

Sorafenib 200 mg Tablet

The Only Approved Systemic Therapy for HCC

Temonix

Temozolomide 100 mg & 250 mg Capsule

The One & Only Standard Treatment Option for GBMs

New Products launching in the year

Hexinor

Trihexyphenidyl HCl 2 mg tablet

makes every move easy

MEROCON

Meropenem 500 mg & 1 gm

Paramount Hope in Critical Hours

MEDRINA

Medroxyprogesterone Acetate USP 5 mg Tablet

Marvellous and effective for femina

Amekast

Montelukast 4 mg, 5 mg & 10 mg tablet

Inspires every breath

Lubilax

Lubiprostone 8 mcg & 24 mcg capsule

Chloride Channel-2 activator for the management of Constipation

Milran

Milnacipran HCl INN 50 mg tablet

For the entire management of Fibromyalgia

Mirapin

Mirtazapine

First fast dissolving antidepressant drug in Bangladesh

Regab

Pregabalin 25 mg, 50 mg & 75 mg capsule

A Novel Drug for Chronic Pain

Our Products

Sl. No.	Brand Name	Generic Name
1	Acebid Tab	Aceclofenac 100mg
2	Acupain Tab	Ketorolac Tromethamine 10mg
3	Acupain 30 Inj	Ketorolac Tromethamine 30 mg
4	Agotin Tab	Agomelatine 25mg
5	Alertadin Tab	Desloratadine 10mg
6	Allion Tab	Vitamin & Minarals Multi Vitamin & Multi Minerals
7	Amekast 4 Tab	Montelukast 4 mg
8	Amekast 5 Tab	Montelukast 5 mg
9	Amekast 10 Tab	Montelukast 10 mg
10	Amlocom Tab	Amlodipine 5 Mg + Atenolol 50 Mg 50mg+5mg
11	Amlowide Tab	Amlodipine 5mg
12	Amlozep 10 Cap	Amlodipine 5 Mg + Benazepril HCL 10 Mg 10mg+5mg
13	Amovast Tab	Amlodipine 5mg + Atorvastatin 10mg 5 mg Amlodipine + 10 mg Atorvastatin
14	Anastrol Tab	Anastrozole 1 mg
15	Becovir Tab	Tenofovir Disoproxil Fumarate 300 mg
16	Bevastim Injection	
17	Bukof Tab	Butamirate Citrate 50 Mg SR 50mg
18	Caviral Tab	Entecavir 0.5 mg
19	Carboplat 150 Inj	Carboplatin 150 mg
20	Carboplat 450 Inj	Carboplatin 450 mg
21	Cardisan Tab	Losartan Potassium. 50mg
22	Cardisan Plus Tab	Losartan Potassium & Hydrochlorothiazide. 50mg + 12.5mg
23	Copeg Cap	Ribavirin 200 mg
24	Combiplat Tab	Clopidogrel 75mg + 75mg
25	Coxitor 60 Tab	Etoricoxib 60mg
26	Coxitor 90 Tab	Etoricoxib 90mg
27	Criston 1 Injection	Vincristine 1mg
28	Criston 2 Injection	Vincristine 2mg
29	Cyclotox 200 Injection	Cyclophosphamide 200mg
30	Cyclotox Injection	Cyclophosphamide 1gm
31	Cytabin Injection	Cyterabine 100 mg
32	Docexan 20 Injection	Docetaxel 20 mg
33	Docexan 80 Injection	Docetaxel 80 mg
34	Eptase Inj	Streptokinase BP 15,00,000 IU
35	Eparin-60 Inj	Enoxaparin 60mg
36	Eposis Inj	Erythropoietin Concentrated Solution BP 2000 IU
37	Eposis 3000 Inj	Erythropoietin Concentrated Solution BP 3000 IU
38	Eposis 4000 Inj	Erythropoietin Concentrated Solution BP 5000 IU
39	Eposis 5000 Inj	Erythropoietin Concentrated Solution BP 5000 IU
40	Erlonix 100 Tab	Erlotinib 100 mg
41	Erlonix 150 Tab	Erlotinib 150 mg
42	Erubin 10	Epirubicin

Our Products

Sl. No.	Brand Name	Generic Name
43	Erubin 15	
44	Esoprex 20 Cap	Esomeprazole 20mg
45	Esoprex 40 Cap	Esomeprazole 40mg
46	FAP 500 mg Tab	Paracetamol + Caffain 500mg
47	FAP Plus Tab	Paracetamol + Caffain 500mg + 65mg
48	Filgrast Injection	Filgrastim 300 mcg/0.5 ml
49	Flexibac Tab	Baclofen 10mg
50	Flexibac 5 Tab	Baclofen 5mg
51	Flexibac 25 Tab	Baclofen 25mg
52	Fluroxan 250 Injection	Fluorouracil 250mg
53	Fluroxan 500 Injection	Fluorouracil 500mg
54	Folinex 50 Injection	Calcium Folate 50mg
55	Furo Plus Tab	Furosemide 20mg + Spironolactone 50 Mg 50mg+20mg
56	Gabamax Tab	Gabapentin 300mg
57	Gastroloc Tab	Ranitidine 150mg
58	Gemif Tab	Gemifloxacin 320mg
59	Gemoxen 200 Injection	Gemcitabine HCl 200mg
60	Gemoxen Injection	Gemcitabine HCl 1gm
61	Hexinor Tab	Trihexyphenidyl HCl
62	Imanix Tablet	Imatinib 100mg
63	Interon Inj	Interferon alfa-2a BP 4.5 MIU
64	Kidcef PFS	Cefpodoxime Proxetil 50mg
65	Leukin Tab	Mercaptopurine 50 mg
66	Lexel Tab	Letrozole 2.5 mg
67	Liqu-E (Bot) Cap	Vitamin-E 200mg
68	Liqu-E (Blis) Cap	Vitamin-E 200mg
69	Liqumint Cap	Peppermint Oil 0.2ml
70	Liquical Cap	Calcitriol 0.25mcg
71	Lubilax Cap	Lubiprostone 8 mcg
72	Merocon 500 Inj	Meropenam 500mg/10ml
73	Merocon Inj	Meropenam 1g/20ml
74	Noburn Tab	Domperidone 10mg
75	Paraciv Inj	Paracetamol BP 1000 mg/100 ml
76	Paricon 1 Cap	Paricalcitol 1mcg
77	Paloxi Tab	Palonosetron Hydrochloride INN 0.5 mg
78	Paloxi 0.075 Inj	Palonosetron Hydrochloride INN 0.075 mg
79	Paloxi 0.25 Inj	Palonosetron Hydrochloride INN 0.25 mg
80	Pegin Inj	Peginterferon alfa-2a INN 180 mcg
81	Pegin 135 Inj	Peginterferon alfa-2a INN 135 mcg
82	Platinex 10 Inj	Cisplatin 10 mg
83	Platinex 50 Inj	Cisplatin 50 mg
84	Plasmex IV Infusion	6% HES in Isotonic NaCl Solution 6%

Our Products

Sl. No.	Brand Name	Generic Name
85	Pradox Inj	Pralidoxime Chloride 1000 mg Inj
86	Prasulet 5 Tab	Prasugrel 5mg
87	Prasulet 10 Tab	Prasugrel 10mg
88	Prokind Tab	Propenthaline Bromide. 15mg
89	Protebon-D Tab	Calcium 500mg + Cholecalciferol 200IU
90	Protebon-M Tab	Calcium + Vit-D + Minerals
91	Protoloc 20 Tab	Pantoprazole 20mg
92	Protoloc 40 Tab	Pantoprazole 40mg
93	Quixin Tab	Levofloxacin 500mg
94	Regab 25 Cap	Pregabalin 25 mg
95	Regab 50 Cap	Pregabalin 50 mg
96	Regab 75 Cap	Pregabalin 75 mg
97	Rituxim 100 Inj	Rituximab 100 mg
98	Rejubion Tab	Vitamin - B1 + B6 + B12
99	Rejubion Inj	Vitamin - B1 + B6 + B12
100	Roflast Tab	Roflumilast 500 mcg
101	Rubicin Inj	Daunorubicin 20 mg
102	Rupadin Tab	Rupatadine 10mg
103	Simpli-3 Tab	Azithromycin 500mg
104	Simpli-3 Inj	Azithromycin Inj 500mg
105	Simpli-3 PFS	Azithromycin 4mg
106	Simpli-3 PFS	Azithromycin 4mg
107	Soranix Tab	Sorafenib 200 mg
108	Spasverin Tab	Alverine Citrate 60mg
109	Starcef Cap	Cefixime Trihydrate 200mg
110	Starcef PFS	Cefixime Trihydrate 100mg/5ml
111	Sunitix Cap	Sunitinib 50 mg
112	Tamolex 10 Tab	Tamoxifen 10 mg
113	Tamolex 20 Tab	Tamoxifen 20 mg
114	Tinizol DS Tab	Tinidazole BP 1000 mg
115	Tenoflex Tab	Tenoxicam 20mg
116	Tivis Tab	Tiemonium Methylsulfate 50mg
117	Tivis Inj	Tiemonium Methylsulfate 5mg/2ml
114	Topoxin	Etoposide 100 mg
115	Trexonate Tab	Methotrexate BP 2.5 mg
116	Trexonate 10 Tab	Methotrexate BP 10 mg
117	Trexonate Inj	Methotrexate 50 mg
118	Veripel SR Cap	Mebeverine HCL 250mg
119	Trexonate Tab	Methotrexate BP 2.5 mg
120	Trexonate 10 Tab	Methotrexate BP 10 mg
121	Trexonate Inj	Methotrexate 50 mg
122	Veripel SR Cap	Mebeverine HCL 250mg

Our Products

Sl. No.	Brand Name	Generic Name
122	Xaloplat 50 Inj	Oxaliplatin 50 mg
123	Xaloplat 100 Inj	Oxaliplatin 100 mg
124	Xbac Tab	Ciprofloxacin 500mg
125	Xbac 750 Tab	Ciprofloxacin 750mg
126	Xbac IV Infusion	Ciprofloxacin 200 mg/100 ml
127	Xbac PFS	Ciprofloxacin 100mg/5ml
128	Xefrim 250 Tab	Cefuroxime axetil 250mg
129	Xefrim PFS	Cefuroxime axetil 125 mg/ 5ml
130	Xelopes 20 Cap	Omeprazole 20mg
131	Xelopes 40 Cap	Omeprazole 40mg
132	Xelopes Inj	Omeprazole 40mg
133	Xelpac 100 Inj	Paclitaxel 100mg
134	Xelpac 30 Inj	Paclitaxel 30 mg
135	Xelpac 300 Inj	Paclitaxel 300mg
136	Xemocid IV Infusion	Amino Acid 0.25mcg
137	Xemocid gold IV Infusion	Amino Acid 500 MI
138	Xenofer 100 Inj	Iron Sucrose (100 Mg Elemental Iron In 5 MI) 100mg
139	Xenofer 50 Inj	Iron Sucrose (100 Mg Elemental Iron In 5 MI) 50mg
140	Xenosol 100 IV Infusion	Sodium Chloride BP 0.9% w/v (Normal saline)
141	Xenosol 250 IV Infusion	Sodium Chloride BP 0.9% w/v (Normal saline)
142	Xenosol 500 IV Infusion	Sodium Chloride BP 0.9% w/v (Normal saline)
143	Xeroder 50 Cap	Fluconazole 50mg
144	Xeroder 150 Cap	Fluconazole 150mg
145	Xeroder IV Infusion	Fluconazole 200 mg/100 ml
146	Xerova 10 Tab	Atorvastatin 10mg
147	Xerova 20 Tab	Atorvastatin 20mg
148	Xevirol Tab	Everolimus 10 mg
149	Xevirol 5 Tab	Everolimus 5 mg
150	Xitabin Tab	Capecitabine 500 mg
151	Xoleron Inj	Zoledronic Acid 4 mg
152	Xolitra Tab	Flupentixol HCL+ Melitracen HCL 0.5 mg Flupentixol+ 10 mg Melitracen
153	Xorubin 10 Inj	Doxorubicin 10 mg
154	Xorubin 50 Inj	Doxorubicin 50 mg
155	Xovir IV Infusion	Acyclovir 250mg
156	Xovir 500 IV Infusion	Acyclovir 500mg
157	Xtrapel Cap	Tramadol Hydrochloride. 100mg
158	Xtrapel 50 Cap	Tramadol Hydrochloride. 50mg
159	Xtrapel Inj	Tramadol Hydrochloride. 100mg
160	Xvit Cap	Zn, Iron, Folic Acid, B-vitamins, Vit-C
161	Zytix Tablet	

Marketing Team & General workforce





Marketing Team & General workforce





ADDITIONAL INFORMATION

[illegible]

[illegible]

[illegible]



Proxy Card

This Proxy card is for use at the Annual General Meeting of Beacon Pharmaceuticals Limited to be held on Wednesday, December 18, 2013.

I/We.....

Having BO ID #

of.....

Being a member of the Company do hereby appoint Mr./Ms.

of to be my/our proxy to attend and vote on my/our behalf at the 12th Annual General Meeting of the Company to be held on Wednesday, December 18, 2013 at 10.00 a.m at the Factory Premises of Beacon Pharmaceuticals Limited at Kathali, Bhaluka, Mymensingh and at any adjournment thereof.

Signature of Proxy

Revenue
Stamp of
Tk.10/-

Signature of the Shareholder

Notes:

This form of proxy, duly completed, must be deposited at least 48 hours before the meeting at the Company's Share department at 153-154, Tejgoan Industrial Area, Dhaka-1208, Bangladesh. Proxy will be invalid if not signed and stamped as shown above. Signature of the shareholder should agree with the specimen signature registered with the Company.



Attendance Slip

I do hereby record my attendance of the 12th Annual General Meeting of the Company to be held on Wednesday, 18 December 2013 at 10.00 a.m at the Factory Premises of Beacon Pharmaceuticals Limited at Kathali, Bhaluka, Mymensingh.

Name of the Shareholder :

Folio No : Nos. of shares held :

BO ID :

Signature of the Shareholder/Proxy

Dated :

Notes:

Shareholders attending the meeting in person or by proxy are requested to deposit the attendance slip duly filled in at the entrance of the meeting hall. Seats in the auditorium are reserved only for the shareholders/proxies.